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Abstract 
The hypoxia of high altitude (‘hypobaric hypoxia’) presents a profound physiological 
challenge to the human body and at extreme high altitude the human body nears the 
limits of its tolerance for oxygen deprivation. Physical performance in this environment 
is limited by two major physiological elements: ‘acclimatisation’ to hypobaric hypoxia 
sufficient to allow strenuous physical exertion, and the avoidance of Acute High 
Altitude Illnesses (AHAI). The rate and effectiveness of acclimatisation and the 
susceptibility to AHAI varies markedly between individuals, suggesting a possible 
genetic influence on high altitude performance. 
A polymorphism of the human Angiotensin Converting Enzyme (ACE) gene has been 
identified in which the deletion (D-allele), rather than the insertion (I-allele), of a 287 
base pair sequence is associated with higher circulating and tissue ACE activity. This 
polymorphism has also been associated with physical performance phenotypes, the 
ACE I-allele being associated with elite endurance performance. An excess frequency 
of the ACE I-allele has also been identified in a small sample of elite UK high altitude 
mountaineers.  
This thesis set out to test the hypothesis that the ACE I-allele is indeed associated with 
successful physical performance at high altitude, and to explore the mechanism by 
which such an advantage may be mediated. I conducted a series of prospective gene-
environment interaction studies to assess whether the ACE I-allele is associated with 
successful ascent to high altitude and, if such an advantage exists, whether this is 
mediated by reduced susceptibility to Acute Mountain Sickness (AMS) or improved 
oxygen saturations. To further define the underlying mechanism, I explored the 
association of bradykinin 2 receptor genotype with high altitude performance to 
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investigate whether the ACE I allele contribution is mediated by increased kinin 
activity. Additionally I extended these observations to those who have faced the most 
extreme hypoxic challenge - a successful ascent of Mount Everest. 
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“I am nothing more than a single narrow gasping lung, floating above the mists and 
summits.” 
 
Reinhold Meissner, the first human to reach the summit of Mount Everest without the 
use of supplemental oxygen. 
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1.1 Humans at high altitude 
1.1.1 Hypobaric hypoxia of high altitude 
“We live submerged in an ocean of air, which by unquestioned experiments is known to 
have weight.” Evangelista Torricelli (1608-1647)(1) 
As altitude above sea level increases, the barometric pressure falls, resulting in a 
decreased atmospheric partial pressure of oxygen. Oxygen is critical to normal cellular 
function: acting as the ultimate proton acceptor of the mitochondrial electron transport 
chain, it is essential to aerobic cellular ATP synthesis. As such, the hypoxia of high 
altitude (‘hypobaric hypoxia’) presents a profound physiological challenge to the human 
body. At extreme high altitude the human body nears the limits of its tolerance for 
oxygen deprivation. An arterial blood gas taken from a healthy individual at 8400m 
near the summit of Mount Everest recorded a partial pressure of arterial oxygen (PaO2) 
of 2.55 kPa (2) and acute exposure to this degree of hypoxia would be rapidly fatal (3). 
However, with time, adaptive change (‘acclimatisation’) does allow some individuals to 
survive such extreme hypoxia.  
1.1.2 High altitude performance 
High-altitude mountaineers perform extreme endurance exercise in a hypoxic 
environment. Altitude regions have previously been defined as high altitude (1500-3500 
m), very high altitude (3500-5500 m), and extreme altitude (>5500 m) (4). In addition to 
the isolated hypoxic physical challenge, safe and successful ascent and descent of 
mountains can be threatened by a diverse range of hazards that include extremes of 
temperature and weather, trauma, hypothermia and high altitude illness (5, 6). If the 
objective dangers are avoided, survival and performance at high altitude are limited by 
two major physiological elements: acclimatisation to hypobaric hypoxia sufficient to 
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allow strenuous physical exertion, and the avoidance of Acute High Altitude Illnesses 
(AHAI). The rate and effectiveness of acclimatisation and the susceptibility to AHAI 
varies markedly between individuals, suggesting a genetic influence on high altitude 
performance (7, 8). 
1.1.3 Acclimatisation to hypobaric hypoxia 
Acclimatisation is the set of beneficial processes whereby lowland humans respond to a 
reduced partial pressure of oxygen (PO2) in inspired air. The systemic changes of 
acclimatisation, as classically described, include hyperventilation, polycythemia, 
changes in oxygen affinity of haemoglobin, and angiogenesis in peripheral muscle and 
have been extensively described (9). These processes tend to increase convective 
oxygen delivery to the tissues and take weeks or perhaps even months to optimize 
hypoxic acclimatisation. The importance of some of these classical mechanisms have 
been challenged, with the benefit of increased 2,3-DPG in shifting the haemoglobin 
oxygen dissociation curve to the left having little effect in vivo (10) and the increases in 
capillarisation and mitochondrial density appearing only marginal (11). 
The Ventilatory Response to Hypoxia.  
Exposure to hypoxia results in stimulation of the peripheral chemoreceptors, principally 
the carotid bodies, which sense the low PO2 in arterial blood (12). Acute hypoxia 
stimulates an immediate increase in minute ventilation that peaks within minutes and 
then declines towards pre-hypoxic levels over the following minutes-to-hours. At high 
altitude, sustained hypoxia causes ventilation to rise again over subsequent hours, 
surpassing acute hypoxic levels and continuing to rise for several days. It is believed 
that oxygen-regulated alterations in gene expression cause changes in carotid body and 
ventral medullary function (13). This progressive increase in ventilation is known as 
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ventilatory acclimatisation to hypoxia, and the resultant elevation in arterial PO2 
mitigates the impact of environmental hypoxia.  
The Cardiovascular Response to Hypoxia.  
Acute hypoxia stimulates a progressive increase in cardiac output over several days, 
associated with an elevation in heart rate rather than stroke volume. Cardiac output 
gradually normalises as individuals acclimatise, although heart rate may remain high 
accompanied by a lower stroke volume (14, 15). Prolonged hypobaric hypoxia is 
associated with sustained, but reversible, changes in cardiac mass, stroke volume, 
function, and energy metabolism (16). Maximal cardiac output decreases with 
acclimatisation (both maximal stroke volume and maximal heart rate fall) and this is not 
explained by hypovolaemia, acid-base status, polycythaemia, autonomic changes or 
impaired systolic function. Pulmonary artery pressure remains persistently elevated and 
rises further with exercise (14).  
Polycythaemia in Response to Hypoxia.  
On arrival at high altitude, haemoconcentration occurs secondary to insensible losses, 
third space fluid redistribution, hormonal induced diuresis and altered thirst (17). 
However an increase in the secretion of erythropoietin is detectable within 90 minutes 
of exposure to acute hypoxia (18) and induces a true increase in haemoglobin 
production that develops slowly, taking several days to initiate and continuing to rise for 
up to eight months. This haemoglobin increase is unlikely to be an important factor in 
acclimatisation over the first days to weeks at altitude but subsequently the combination 
of increased haemoglobin and ventilatory acclimatisation can result in a blood oxygen 
content that may even exceed that at sea level (2). 
 
   17 
Cellular mechanisms of acclimatisation.  
Increasingly well characterized but incompletely elucidated are the molecular and 
cellular changes that are associated with acclimatisation (19-21). Supporting the concept 
of cellular changes in acclimatisation are studies that demonstrate that maximal 
systemic exertional oxygen uptake (VO2max), cardiac output and skeletal muscle 
metabolism alter in response to hypobaric hypoxia and that these changes are not 
reversed by normoxia (16, 22, 23). Some authors have attributed the reduction in 
VO2max to a redistribution of blood flow to non exercising tissue (22) however others 
have proposed that hypoxia drives a coordinated transcriptional response that minimises 
hypoxic injury, redresses oxygen debt and achieves cellular acclimatisation by 
decreasing cellular oxygen demand (3). This concept of a reduced energy state is 
supported by hypoxia induced alterations in skeletal muscle metabolic substrate patterns 
and mitochondrial biogenesis that may optimise energy metabolism and reduce 
oxidative stress (7, 21, 24-26). Cellular hypoxia tolerance has been demonstrated in 
skeletal muscle with changes in glucose metabolism from oxidative to more anaerobic 
ATP production providing reduced oxidative stress and acute protection of myofibres 
against lethal ischemia (16, 26, 27). 
 
Hypoxia-inducible factor and oxygen sensitive control of gene transcription 
The hypoxia-inducible factor (HIF) family of transcription factors is now known to play 
a central regulatory role in these homeostatic changes at both the systemic and cellular 
levels; HIF directly or indirectly regulates several hundred genes, coordinating the 
response to hypoxia and initiating a wide spectrum of physiological responses that 
include changes in mitochondrial energy utilization, anaerobic metabolism, 
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erythropoiesis, angiogenesis and ventilation via the function of the carotid body 
chemoreceptor (28).  
 
HIF-1 is a heterodimer consisting of HIF-1β dimerised to an alpha subunit (one of HIF-
1α, 2α or 3α). HIF-1α and HIF-2αβ heterodimers activate transcription of oxygen 
regulated target genes. Under normoxic conditions, HIF-α is continuously expressed 
and rapidly degraded whereas under hypoxic conditions, prolyl hydroxylation and 
proteasomal degradation are slowed, resulting in stabilisation and accumulation of HIF-
α. The HIF-α subunit is then translocated to the nucleus where it dimerises with HIF-β, 
binds to the hypoxia response elements (HRE) of HIF-target genes and activates their 
transcription. The HRE is present in more than 70 genes (28).  
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1.2 Renin Angiotensin Systems  
1.2.1 Circulating RAS 
The endocrine Renin Angiotensin System (RAS) is a key homeostatic regulator of fluid 
balance and blood pressure. In response to decreased afferent arteriolar pressure, 
decreased filtered sodium load in the nephron ultra-filtrate or to sympathetic nervous 
stimulation, the renal juxtaglomerular apparatus releases the aspartyl protease, renin 
(29). Renin cleaves hepatically-derived angiotensinogen to yield angiotensin I. 
Angiotensin-converting-enzyme (ACE) is a key component of the RAS and hydrolyses 
Angiotensin I to generate octapeptide Angiotensin II (30).  Two receptors, AT1R and 
AT2R, mediate the effects of Angiotensin II, although the roles of the AT2R are less 
well defined. Angiotensin II binding to AT1R causes an elevation in arterial blood 
pressure through both salt and water retention provoked by adrenal aldosterone release, 
and direct arterial vasoconstriction. Via this vasoconstrictor action, Angiotensin II has a 
role in mediating hypoxic pulmonary vasoconstriction. (31-33). Angiotensin II is 
degraded by vascular and erythrocyte angiotensinases to Angiotensin III and 
Angiotensin IV, which have similar circulatory effects to that of Angiotensin II.  
Angiotensin IV also has its own specific functional receptor (34).  
ACE also cleaves the vasodilator bradykinin, a 9-amino acid peptide member of the 
kinin-kallikrein system (35). Bradykinin is a potent endothelium-dependent vasodilator 
that has a brief duration of action with a plasma half-life of approximately 15–30 
seconds due to its rapid degradation by ACE (36, 37). As such, ACE efficiently breaks 
down approximately 95% of bradykinin in a single passage through the pulmonary 
circulation (38). It also causes contraction of non-vascular smooth muscle in the 
bronchus and gut and increases vascular permeability. Bradykinin acts upon the 
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bradykinin type-1 receptor (BK1R), induced by tissue injury, and the constitutively 
expressed BK2R, which stimulates a variety of inflammatory and vascular responses 
and which may engage in cross-talk with other RAS components (39-43). Bradykinin 
levels are inversely related to ACE activity (41) with increasing circulating ACE 
activity diminishing hypotensive responses due to reduced vasodilation via BK2 
receptor activation. 
Figure 1.1 Circulating Renin Angiotensin System (adapted from Woods and 
Montgomery 2001). 
 
 
In addition, a second angiotensin converting enzyme (Angiotensin converting enzyme 
2, or ACE2), not only generates Angiotensin II from Angiotensin I but also acts upon 
Angiotensin II to synthesise Angiotensin (1-7), an angiotensin I heptapeptide (44, 45). 
Angiotensin (1-7) acts through the Mas receptor (46), and produces vasodilation via 
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activation of bradykinin and nitric oxide. ACE2 therefore negatively regulates the RAS 
and acts as an endogenous ACE inhibitor through alterations in formation of 
angiotensin II and angiotensin (1-7). 
 
1.2.2 Local tissue RAS 
In addition to the classical circulating RAS, a local RAS has now been identified in 
tissues as diverse as the heart (47), kidney (48), vasculature (49), adipose tissue (50), 
liver (51), nervous tissue/brain (48), adrenals (52), gonads/reproductive system (53), the 
gastrointestinal system (54) and the pancreas (49, 55). Such local RAS are believed to 
have paracrine, autocrine and intracrine roles that include the regulation of cell growth, 
differentiation, apoptosis, and proliferation; metabolism and generation of reactive 
oxygen species and free radicals; tissue inflammation and fibrosis; local 
haemodynamics; and hormonal secretion and reproduction (56-58) (49, 59-62).  
.  
1.2.3 RAS and altitude 
The central role of the classical RAS in circulatory homeostasis has long suggested a 
role in the acclimatisation to hypobaric hypoxia (63-69). Early studies demonstrated 
that ACE activity changed during the acclimatisation response with circulating ACE 
activity falling on exposure to high altitude (69), and more so amongst ‘good 
acclimatisers’ (66).  
There is a range of proposed mechanisms by which RAS may influence the processes 
involved in acclimatisation to high altitude discussed above. Angiotensin II is known to 
modulate hypoxic pulmonary vasoconstriction and this response is attenuated by AT1 
receptor antagonism (70) and ACE inhibition (71). Furthermore, pharmacological 
inhibition of ACE activity reduces pulmonary artery pressures in patients with high 
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altitude pulmonary hypertension (72).  
Angiotensin II may additionally have a role in the regulation of hypoxic respiratory 
drive, through modulation of carotid body chemoreceptor activity (73) and its central 
transduction (74).  
The RAS has been implicated in the control of erythropoiesis by observations that ACE 
inhibitors have proved effective for the treatment of secondary polycythaemia following 
renal transplant (75). Proposed mechanisms for this effect include lowering of 
erythropoietin production by increasing renal blood flow; a fall in sodium reabsorption 
and, thus, in oxygen consumption, which leads to increased oxygen availability for 
erythropoietin-producing cells; and interruption of a direct effect that angiotensin II 
might have on erythropoiesis (76), possibly mediated by an up-regulation of angiotensin 
type 1 receptors on erythroid precursors (77). Furthermore, ACE inhibitors have been 
demonstrated to ameliorate the polycythaemia of chronic mountain sickness (78). 
Meanwhile, exercise-related sodium and fluid retention occur at HA and may contribute 
to AMS and pulmonary interstitial edema. A potential beneficial adaptation of RAS is 
that the plasma renin-induced release of aldosterone is blunted at altitude, which in turn 
may encourage natiuresis and diuresis (67, 79). 
Contributing to successful adaptation to high altitude may be the RAS influence on 
metabolic efficiency and muscle fibre type that is described later and which is argued to 
contribute to its role in sea level athletic performance (80-83). It has been proposed that 
metabolic efficiency is likely to be increasingly important in the hypoxic environment 
of high altitude and that RAS may influence the cellular and molecular elements of 
hypoxic acclimatisation (3). 
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1.3 RAS polymorphisms associated with physical performance 
1.3.1 ACE Insertion / Deletion polymorphism 
Several functional polymorphic variants of the genes encoding various RAS 
components have been identified, but the most extensively studied is the ACE Insertion 
/ Deletion polymorphism. The presence (insertion, I) rather than absence (deletion, D) 
of a 287 base-pair fragment Alu repeat sequence within intron 16 of the ACE gene is 
associated with lower circulating ACE activity and the accounts for 47% of the total 
phenotypic variance of serum ACE in Caucasians (84). Similar findings exist in cardiac 
tissue and in monocytes (47, 85).  
In 1998 this ACE I/D polymorphism was the first gene variant to be associated with 
human physical performance (86). In these early studies, the I-allele was demonstrated 
to be strongly associated with fatigue resistance. Maximum duration of a standardized 
repetitive elbow flexion exercise (using a 15 kg barbell) was recorded in 78 Caucasian 
military recruits before and after 10 weeks of identical military training. Baseline 
performance was independent of ACE genotype, unlike improvements in exercise 
duration with training, which were strongly genotype-dependent; gains of 79.4 +/- 25.2 
and 24.7 +/- 8.8 seconds were seen in those of I/I and I/D genotype, respectively (p = 
0.005 and 0.007), but not in D/D homozygotes (7.1 +/- 14.9 seconds; p = 0.642). The I/I 
homozygotes thus showed an 11-fold greater improvement than those of D/D genotype 
(87). This association with endurance performance was supported by Myerson et al. 
who demonstrated in a group of 91 elite British runners that I-allele frequency increased 
with competitive distance, from 0.35 to 0.53 and 0.62 for the three distance groups 
200m, 400–3000 m and 5000 m, respectively (p = 0.009 for linear trend) (88). In part, 
this seems to be related to enhanced training-related oxygen economy (89) and 
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metabolic efficiency (80). 
Strong ACE I/D genotype-dependent associations were seen in other responses to 
physical training with an exaggerated left ventricular growth response association with 
the ACE D-allele in 140 Caucasian male military recruits following a 10 week physical 
training programme (87).  
Since these landmark studies, a significant body of literature has developed to support 
these associations and this has been recently reviewed by Puthucheary et al. (90). The 
mechanisms underlying the association with physical performance have not been fully 
elucidated but ACE I/D genotype dependent differences in cardiac muscle growth (87, 
91), skeletal muscle (92) and metabolic efficiency (80, 93-95) have been demonstrated. 
Although conflicting data exist, the I allele appears to be associated with elite endurance 
events (88) and the D allele with strength and power performance in Caucasians. This 
association is ethnicity/race dependent and not seen in subjects of black African origin 
(96), amongst whom ACE I/D genotype has little influence on ACE activity (97). 
 
1.3.2 Bradykinin receptor polymorphisms 
The central role of ACE in the RAS and the biological plausibility that the ACE I/D 
functional polymorphism has a significant role in performance is strengthened by 
studies of other functional polymorphisms in the RAS. The role of ACE in cleaving 
bradykinin means that bradykinin levels are inversely related to ACE activity (41). The 
biological action of bradykinin is mediated through the activation of two G-protein-
coupled kinin receptor subtypes, the inducible bradykinin type 1 (BK1R) and 
constitutive type 2 (BK2R) receptors. The vascular BK1 receptor is normally expressed 
very weakly but is markedly upregulated in the presence of inflammation and 
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cardiovascular disease (98, 99). The endothelial cell associated BK2R is constitutively 
expressed in most tissues, and is most highly expressed in the pulmonary vasculature. It 
is considered a much stronger mediator of vasodilation through increased production 
and release of nitric oxide at the endothelial level (100, 101). 
In humans, the BK2R gene has been mapped to chromosome 14q32, is more than 25 kb 
in size, and consists of three exons. It demonstrates a common functional polymorphism 
in which the absence (-9) of a 9 base pair repeat is associated with greater gene 
transcription (102) and higher mRNA expression of the receptor (103), while its 
presence (+9) is associated with increased vascular tone and systemic hypertension 
(104). The -9 allele has been shown to be associated with greater skeletal muscle 
metabolic efficiency (ratio of internal work performed to external work measured) 
(105). If part of the effect of the ACE I/D polymorphism on performance is mediated by 
increased bradykinin activity, the combination of the ACE I-allele and the BK2R -9 
allele should confer ‘high kinin receptor activity’ and potentiate the phenotypic 
advantage of this state. This ACE I / BK2R -9 allele combination has been associated 
with endurance performance in a study of 81 Olympic-standard track athletes, and 
altered left ventricular growth in response to physical training (105, 106). 
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1.4 ACE I/D polymorphism and high altitude 
 
1.4.1 ACE I/D polymorphism and high altitude performance 
Given the association between the ACE I/D polymorphism and elite athletic 
performance, it appeared possible that an I-allele association with hypoxic performance 
might exist. Montgomery et al. demonstrated the first association between ACE I/D 
polymorphism and high altitude performance in a small group of elite high altitude 
mountaineers (86, 107). ACE I/D genotype was determined in 25 male mountaineers 
who had ascended to over 7000m without supplementary oxygen and compared with 
that of 1,906 healthy British males. ACE I/D genotype distribution and allele frequency 
differed significantly between climbers and controls (P=0.02 and 0.003 respectively), 
with a relative excess of II genotype and deficiency of DD genotype found in the 
climbers. Among the 15 climbers who had ascended beyond 8,000 m without oxygen, 
none was homozygous for the D allele (6 II and 9 ID: I allele frequency = 0.65). 
Although the association between the ACE I/D and elite high altitude mountaineers 
remained highly topical in subsequent years (81, 88, 89, 94, 107-109), no further studies 
attempted to confirm the finding of this small retrospective study.  
 
The partial pressure of oxygen at an altitude of 5000m is approximately half that at sea 
level, and this presents a significant but lesser physiological challenge than that endured 
at extreme high altitude. The large cohort of recreational climbers and trekkers who 
undertake ascents to lesser altitudes may represent a different group to those attempting 
to reach 8000m (6). However, a prospective study of 284 climbers attempting to climb 
to the summit of Mt. Blanc (4,807 m) supported an association between the ACE I-
allele and successful performance in the hypoxic environment. Success in reaching the 
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summit was genotype dependent (87.7% of DD, 94.9% of ID and 100% of II 
individuals; p=0.048); I-allele frequency for those reaching the summit was 0.47 
compared to 0.21 for those who did not (p=0.01) (110). 
 
Table 1.1 ACE I/D and ascent to altitude. 
Study Subjects Altitude I/D association 
Montgomery et al. 1998 (86) 25 British elite mountaineers >7000m I allele and elite status  
Tsianos et al. 2005 (110) 284 climbers Ascent to 4807m I allele and successful ascent 
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1.4.2 ACE I/D and acclimatisation 
The findings of Montgomery et al. that the ACE I-allele was overrepresented in elite 
high altitude mountaineers (86) resulted in a series of studies to identify the mechanism 
by which the ACE I/D polymorphism exerts an influence over high altitude 
performance.  
The ventilatory response to hypoxia is a critical element of successful acclimatisation. 
Woods et al. demonstrated that oxygen saturations (SaO2) in a group of 32 subjects 
ascending to 5000m over 12 days was significantly associated with the ACE genotype 
(p = 0.01) with a relatively sustained SaO2 in the II subjects. This association was not 
evident in a slower (18.5 day) ascent group (111).  Further investigation of the 
mechanism underlying this observation was undertaken by Patel et al. who examined 
whether an altered ventilatory response to hypoxic exercise may contribute to this effect 
(112). Sixty subjects underwent incremental cardiopulmonary exercise testing in 
normoxic and subsequently hypoxic (12.5+/-0.5% oxygen) conditions and demonstrated 
that those of II genotype have an improved hypoxic ventilatory response (HVR) with 
increased minute volume and reduced end tidal CO2. Increased erythropoiesis represents 
another central element of the classical model of acclimatisation, however no 
association was demonstrated between ACE genotype and erythropoietin levels in 63 
endurance athletes exposed to moderate altitude (2200m) for 48 hours (113). 
 
Table 1.2 ACE I/D and acclimatisation. 
Study Subjects Exposure Outcome measure I/D association 
Woods et al. 2002 (111) 32 Caucasians Ascent to 5000m SaO2 I and increased SaO2  
Patel et al. 2003 (112) 60 Caucasians Hypoxic CPEX test HVR and SaO2 I and increased HVR / SaO2 
Gonzalez et al. 2006 (113) 63 Caucasians 48 hours at 2200m EPO levels No association 
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A recent review of ACE genotype and physical performance by Puthucheary et al. 
discussed a range of mechanisms that may explain the association between the ACE I/D 
polymorphism and performance (90). ACE I/D dependent differences in sea level 
cardiac and skeletal muscle responses to training (86, 91, 92), differing metabolic 
efficiency (82) and muscle fibre type (83) may contribute to the impact of ACE 
genotype on high altitude performance. However, to date, these hypotheses have not 
been tested as determinants of successful acclimatisation to hypobaric hypoxia. 
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1.4.3 ACE I/D and Acute high altitude illness (AHAI) 
Although the association between ACE I-allele and improved high altitude performance 
may be conferred by enhanced athleticism, it might also be accounted for by an 
association of the D-allele with illness at high altitude. Acute exposure to hypobaric 
hypoxia or an increase in altitude can induce the pathophysiological responses of AHAI. 
These conditions are Acute Mountain Sickness (AMS), High Altitude Pulmonary 
Edema (HAPE) and High Altitude Cerebral Edema (HACE) (114-116). Susceptibility to 
these debilitating and sometimes fatal conditions prevents successful performance at 
altitude. AHAI aetiology is incompletely understood and individual susceptibility 
highly variable with some individuals predisposed to developing altitude illness (8, 
117): some individuals suffer the life threatening complications of high altitude cerebral 
and pulmonary oedema at altitudes as low as 3000m, whilst others have climbed all 14 
of the world’s 8000m mountains without supplementary oxygen.  
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1.4.4 ACE I/D and Acute Mountain Sickness 
Acute mountain sickness (AMS) is the most common of the altitude diseases. AMS is 
characterised by headache following recent ascent to altitude associated with additional 
symptoms including loss of appetite, nausea, vomiting, fatigue or weakness, dizziness, 
or difficulty sleeping (114-116). The incidence of AMS ranges from 10% to 93%, 
depending on the highest altitude reached and the rate of ascent. It is thought that a 
continuum of cerebral oedema ranges from the mild symptoms of AMS to the extreme 
of coma and death in severe HACE (116). The Lake Louise Scoring (LLS) System can 
be used to quantify AMS and is an important tool in research studies of AMS (118, 
119). Scores are based on patient reports of presence and severity of headache, 
gastrointestinal symptoms, fatigue or weakness, dizziness or lightheadedness and 
difficulty sleeping (Table 2.1).  
 
 
Whilst the pathophysiology of AMS is not fully understood, increased levels of 
aldosterone and fluid retention have been found in persons suffering AMS (120, 121) 
which implicates the RAS in the development of the condition. A large recent study of 
1,326 subjects travelling to an altitude of over 4000m identified low hypoxic ventilatory 
response and arterial oxygen desaturation on exercise as independent risk factors for 
developing severe high altitude illness (117). Previous findings that the ACE I-allele is 
associated with a brisk HVR and high SaO2 (111, 112, 122) may suggest a protective 
role against AHAI.  
 
Conflicting data exist regarding the association of ACE I/D genotype with AMS 
development (8). Tsianos et al. demonstrated an association between the heterozygous 
ACE ID genotype and resistance to AMS (p=0.003) in 284 climbers assessed on arrival 
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from lower altitude at the Gouter Hut (3,807 m), Mt Blanc (110). Conversely no 
association between ACE I/D genotype and AMS was identified in studies of 159 
climbers at 4559m (123) or 103 Nepalese pilgrims attending a religious festival at 
4380m (124).  
Table 1.4 ACE I/D and AMS. 
Study Subjects Altitude (m) I/D association 
Koehle et al., 2006 (124) 103 Nepalese 4380 No association 
Tsianos et al., 2005 (110) 284 Caucasians 3817 ID and reduced AMS 
Dehnert et al., 2002 (123) 159 Caucasians 4559 No association 
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1.4.5 ACE I/D and High Altitude Pulmonary Edema (HAPE) 
HAPE represents a potentially fatal form of non-cardiogenic pulmonary oedema in 
response to hypobaric hypoxia that may develop in otherwise healthy individuals on 
induction to altitudes above 2500m (114, 115). The disorder may be caused initially by 
an exaggerated hypoxic vasoconstriction leading to relative overperfusion of certain 
regions of the lung (125, 126), resulting in capillary endothelial shear stress failure and 
leakage in these pulmonary capillary beds (127). The hypoxic pulmonary 
vasoconstriction response (HPVR) may be partly ACE dependent: hypoxia increases 
pulmonary vascular ACE expression (128) and ACE inhibitors (71), and angiotensin II 
type 1 (AT1) receptor blockers (70) attenuate the HPVR and, among patients 
hospitalized with HAPE, the D-allele is associated with a hyperresponsive hypoxia-
induced increase in pulmonary vascular resistance (129).  
 
Although environmental factors such as altitude and rate of ascent are central to 
developing HAPE, individual susceptibility to HAPE, a phenotype termed as HAPE 
susceptible (HAPE-s) rather than HAPE resistant (HAPE-r) is thought to have a genetic 
basis (8, 130). RAS plays a crucial role in regulation of pulmonary vascular tone and 
functional variants in this system, such as the ACE I/D polymorphism, may thus have a 
role in the exaggerated hypoxic vasoconstriction seen in HAPE-sensitive (HAPE-s) 
subjects when compared to HAPE-resistant (HAPE-r) controls (125, 127). 
 
Several studies have addressed the association between ACE I/D and HAPE 
susceptibility, but with conflicting results (Table 4). Hotta et al. studied 49 Japanese 
HAPE-s subjects and 55 HAPE-r climbers and revealed no significant difference in 
ACE I/D polymorphism distribution between the two groups. However, in the 21 HAPE 
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patients who underwent right cardiac catheterization, the pulmonary vascular resistance 
(PVR), and PVR index (PVRI) were significantly higher in the HAPE-s subjects who 
were D-allele carriers than in the HAPE-s subjects who were I-allele carriers (PVR, p = 
0.015; PVRI, p = 0.028) (129). A study of 19 HAPE-s and 20 HAPE-r Indian men 
demonstrated marked differences in RAS components including plasma renin, 
aldosterone and ACE between the 2 groups but no association with the ACE I/D 
polymorphism (131).  This lack of association was also supported by Dehnert et al.’s 
study of 159 Caucasians at 4559m described earlier (123) and a further study in an 
Indian population (132).  
Table 1.5 ACE I/D and HAPE 
Study Ethnicity HAPE-s HAPE-r Altitude (m) I/D association 
Dehnert et al., 2002(123) Caucasian 25 51 4559 No association 
Hotta et al., 2004(129) Japanese 49 55 2758-3190 D and PVR 
Kumar et al., 2004 (131)  Indian 19 20 3000-3800 No association 
Charu et al., 2006(132) Indian 64 53 3400-5600 D and HAPE-s 
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1.4.6 ACE I/D and High Altitude populations  
The Tibetan and Andean populations have lived at high altitude for millennia and are 
regarded as well adapted to hypobaric hypoxia (133). Interestingly these two groups 
display different adaptive strategies with distinct patterns of genetic adaptation showing 
evidence of positive natural selection in different genes or gene regions (133, 134). 
Tibetans and Sherpas have lower haemoglobin concentrations at high altitude than do 
Han Chinese and Westerners (133, 135). These lower haemoglobin concentrations are 
consistent with the reduced prevalence of chronic mountain sickness in Tibetans 
compared with Andeans (136). Tibetans also exhibit a smaller degree of hypoxic 
pulmonary vasoconstriction compared with Andeans and other high-altitude populations 
(137). High altitude Andeans have lower resting ventilation and lower SaO2 when 
compared with Tibetans (133).  
Despite these differences in adaptation, studies have assessed whether the ACE I/D 
allele has been positively selected in these high altitude populations. Rupert et al. 
determined the ACE I-allele frequency in high altitude native Andeans (>3000m) and 
found a greater frequency than that seen in Caucasians. However the I-allele frequency 
was not different from lowland native American populations suggesting that although 
the I-allele may have facilitated the migration of the ancestral native Andeans to the 
highlands, the ACE insertion allele has not been subsequently selected for in this high 
altitude population (138). The same author did not find any association between the 
ACE I/D genotype and cardiovascular disease in high altitude Andeans in a subsequent 
study (139).  
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Addressing the high altitude population of the Tibetan plateau, who include the Sherpas 
of Nepal and native inhabitants of Ladakh, India, Qadar Pasha et al. undertook a study 
of 3 groups:  high altitude (>3600m) residents, lowlanders who migrated to live at 
altitudes >3600m, and lowlanders. The high altitude residents and migrants had 
significantly higher I allele frequencies than the lowlanders (140). A study of essential 
hypertensive patients in Tibet revealed an association of the D-allele with systemic 
hypertension in high-altitude Tibetan women, but not men (141). 
 
Conversely to both the studies in other high altitude populations and the studies of 
HAPE susceptibility, a study of Kyrgyz high altitude residents demonstrated a strong 
association between the ACE II genotype and high altitude pulmonary hypertension (p 
= 0.003). 
Table 1.6 ACE I/D and High Altitude populations 
Study HA population I/D association 
Rupert et al., 1999 (138) Native Andean I and Andean population 
Qadar Pasha et al., 2001 (140)  Ladahki I and HA residents and migrants 
Gesang et al., 2002 (141) Tibetan  D and hypertension in women 
Aldashev et al., 2002 (142) Kyrgyz highlanders II and HAPH 
Rupert et al., 2003 (139) Native Andean No association with CVD 
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1.5 Thesis rationale and aims  
When this thesis was conceived in 2005, Montgomery et al. had demonstrated that the 
ACE I allele was overrepresented in 25 elite high altitude mountaineers (86) and, 
although a second study had confirmed an association of the I-allele with successful 
ascent at lower altitude (110), no further studies had tested the hypothesis that the ACE 
I-allele is associated with successful physical performance in the hypobaric hypoxic 
environment of extreme high altitude. Nor had the association been adequately explored 
across a range of altitudes. This study set out to test rectify these deficits,  and to begin 
to elucidate the mechanism by which such an advantage may be mediated. The aims of 
my thesis were thus to: 
1. Test the hypothesis that ACE I/D is associated with elite high altitude 
performance by comparing the ACE I/D genotype of mountaineers who succeed 
in climbing to extreme high altitude (8000m) with those who fail. 
2. Investigate the mechanism that mediates the ACE I-allele associated 
improvement in high altitude performance by conducting a series of prospective 
gene-environment interaction studies. SaO2 and susceptibility to Acute Mountain 
Sickness were studied in individuals prospectively exposed to hypobaric 
hypoxia, and related to ACE I/D genotype.  
3. To explore the association of bradykinin receptor-2 genotype (BK2R), such as to 
investigate whether the ACE I/D contribution is mediated by alterations in 
bradykinin activity. 
4. Extend these observations to those who have faced the most extreme hypoxic 
challenge - a successful ascent of Mount Everest (8848m).  
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To this end, Chapter 3 describes a study to assess whether the ACE I-allele is 
association with successful ascent to 8000m. Chapters 4 and 5 describe two further 
prospective studies that assess whether the I-allele advantage may be conferred by 
resistance to AMS or increased SaO2 at altitudes of 2700m to 5895m. Chapter 6 assesses 
whether an ACE I-allele advantage may be mediated by increased kinin activity by 
testing whether there is an association between BK2R +9/-9 polymorphism and 
performance at altitude as assessed by successful ascent, AMS incidence and arterial 
oxygen saturations at 4300m. Chapter 7 describes a retrospective study of 219 climbers 
who have reached the summit of Mount Everest (8848m) and assesses whether the ACE 
I/D and BK2R +9/-9 allele frequencies observed in this elite hypoxia-tolerant cohort 
differ from those of published allele frequencies in race-matched controls. 
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CHAPTER 2: Generic Methods 
2.1 Genotyping 
2.2 Lake Louise Score for Acute Mountain Sickness 
2.3 Pulse oximetry 
 
Additional methodology specific to individual studies is described in subsequent 
chapters. 
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2.1 Genotyping 
Genomic DNA was derived from buccal cells, collected using Whatman sterile, foam 
tipped applicators swabbed vigorously against both cheeks, dampened under the tongue, 
then pressed onto a Whatman FTA microcard (Whatman Bioscience, Abington, 
Cambridge, UK).  
Genotyping was performed by staff at the Centre for Cardiovascular Genetics, 
University College London. 2.0 mm discs were punched from the Whatman FTA 
microcard for preparation. 200 µl of FTA Purification Reagent was added to the disc 
taken from the Whatman FTA microcard and incubated for 5 minutes at room 
temperature. Spent FTA Purification Reagent was removed and discarded using a 
pipette and this process was repeated twice further, for a total of three washes with FTA 
Purification Reagent. 
200 µl of TE-1 Buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 8.0) were then added to 
the disc and incubated for 5 minutes at room temperature. Spent TE-1 Buffer was 
removed and discarded using a pipette and this process was then repeated. 
The disc was then allowed to dry at room temperature for about one hour (or at 56°C for 
10 minutes) before performing Polymerase Chain Reaction (PCR). 
ACE I/D genotyping was performed using PCR primer sequences: 5’ Oligo : FH 76  
Sequence: CAT CCT TTC TCC CAT TTC TC; 5’ insertion oligo: FH77 Sequence: 
TGG GAT TAC AGG CGT GAT ACAG; 3’ oligo: FH78 Sequence: ATT TCA GAG 
CTG GAA TAA AAT T. PCR was performed with amplification conditions as follows: 
initial denaturating temperature 95°C for five minutes, followed by 35 cycles of 95°C 
for 45 seconds, 54°C for 45 seconds and 72°C for 30 seconds and 1 cycle of 72°C for 5 
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minutes. All PCR mixes contained dNTP, 2.5mM final magnesium chloride, and 8µl of 
Taq polymerase in a 2000 µl final reaction volume. Reactions were overlaid with 20µl 
of mineral oil. The PCR products were run on 7.5% microtitre array diagonal gel 
electrophoresis (MADGE) for 30 minutes at 110V. Genotype was determined by 
identifying appropriate bands (Deletion allele 85bp;  Insertion allele, 65 bp). 
 
BK2R +9/-9 genotyping was performed using forward primer 5’ 
TCTGGCTTCTGGGCTCCGAG 3’ and reverse primer 5’ 
AGCGGCATGGGCACTTCAGT 3’. PCR used annealing temperature 63ºC (45 
seconds) and 72°C (one minute). The PCR mix contained dNTP’s, 1.5mM final 
magnesium chloride. PCR products were run on heteroduplex gels at 150V for 2 hours. 
Genotype was determined by identifying appropriate bands (+9, 109 bp; -9, 100 bp). 
 
Genotyping accuracy and reliability. Known control ACE I/D and BK2R +9/-9 
genotypes were run alongside study PCR samples to ensure that the PCR has amplified 
correctly. All genotypes were verified by two independent technicians, who were blind 
to subject data, and discrepancies were resolved by repeat genotyping. Although early 
ACE I/D genotyping techniques were prone to misreading ID as DD (84), the accuracy 
of the three primer PCR method used has been published as 100% (143, 144). The rate 
of failure of the genotyping technique is influenced by the quality of DNA sample 
utilized. In this series of studies, where DNA was derived from buccal cells stored on 
Whatman FTA microcards, the genotyping failure rate is described in each results 
section and ranges from 0 - 1.8% for ACE I/D and 0 - 4.4% for BK2R +9/-9.    
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2.2 Lake Louise Score for Acute Mountain Sickness 
The Lake Louise Consensus Group defined AMS as the presence of headache in an 
unacclimatised person who has recently arrived at an altitude above 2500 m plus the 
presence of one or more of the following: gastrointestinal symptoms (anorexia, nausea, 
or vomiting), insomnia, dizziness, and lassitude or fatigue (119). Several scores exist for 
the diagnosis and assessment of the severity of AMS, including the Lake Louise Score 
(LLS) (119), the Environmental Systems Questionnaire (145) and visual analogue score 
(146). In this thesis, subjects were assessed using the LLS (Table 2.1). Data collection 
on Mount Kilimanjaro and Cerro Aconcagua was undertaken by teams of medical 
students from the Manchester University Medical School, Manchester, UK and the 
Norwegian University of Science and Technology, Tromso, Norway respectively.  
The initial definition of AMS using the LLS was that of a score of 3 or more using the 
self reported symptom score (119). Subsequently there has been significant variation in 
both the threshold score for the diagnosis of AMS and the inclusion of the clinical 
assessment score (116, 118). This thesis presents the numerical Total LLS, which is the 
sum of the self reported Symptom score and the Clinical assessment score (Table 2.1), 
and uses a Total LLS of ≥4 as diagnostic for AMS.  
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Table 2.1 Lake Louise Scoring System for Acute Mountain Sickness 
 
 
 
 
 
  
including insomnia, fa-
t igue (beyond tha t
expected from the day's
activities), dizziness, an-
orexia, and nausea. The
headache often worsens
during the night and with
exertion.4,5 Insomnia is
the next most frequent
complaint. Poor sleep
can occur secondary to
periodic breathing, se-
vere headache, dizziness,
and shortness of breath,
among other causes. An-
orexia and nausea are
common, with vomiting
reported less frequently
in trekkers to 4243 m.6
Many sea-level residents
are surprised on their first
encounter with AMS by
the debilitating lassitude
that strikes. Decreased
urinary output, indepen-
dent of fluid intake, is
common. Diagnostic
physical findings in
AMS only become ap-
parent when the syndrome progresses to HACE. Prior to
such progression, AMS is distinguished only by
symptoms. The progression of AMS to HACE is marked
by altered mental status, including impaired mental
capacity, drowsiness, stupor, and ataxia. Coma may
develop as soon as 24 hours after the onset of ataxia or
change in mental status. The severity of AMS can be
scored using the Lake Louise Questionnaire,7 or the more
detailed Environmental Symptoms Questionnaire (see
Table 1),8 or by the use of a simple analogue scale.9
Today, more than 100 years after the first clear clinical
descriptions of AMS and HACE,2,3 we have advanced
our understanding of the physiology of acclimatization to
high altitude, and the pathophysiology of AMS and
HACE, yet many important questions remain.
The setting
As altitude increases, barometric pressure falls (see
Fig 1). This fall in barometric pressure causes a
corresponding drop in the partial pressure of oxygen
(21% of barometric pressure) resulting in hypobaric
hypoxia. Hypoxia is the major challenge humans face at
high altitude, and the primary cause of AMS and HACE. It
follows that oxygen partial pressure is more important than
geographic altitude, as exemplified near the poles where
the atmosphere is thinner and, thus, barometric pressure is
lower. Lower barometric pressure at the poles can result in
oxygen partial pressures that are physiologically equiva-
lent to altitudes 100 to 200 m higher at more moderate
latitudes.10 We define altitude regions as high altitude
(1500-3500 m), very high altitude (3500-5500 m), and
extreme altitude (N5500 m).11
AMS = Acute mountain
sickness
CA = Carbonic anhydrase
CBF = Cerebral blood flow
HACE = High-altitude
cerebral edema
GI = Gastrointestinal
HAH = High-altitude
headache
HAPE = High-altitude
pulmonary edema
ICP = Intracranial pressure
MRI = Magnetic resonance
imaging
NO = Nitric oxide
PDE = Phospodiesterase
inhibitors
SR = Systematic review
TCD = Transcranial Doppler
RCT = Randomized
controlled trial
VEGF = Vascular endothelial
growth factor
Abbreviations and Acronyms
Table 1
An individual has AMS as assessed by the Lake Louise self-assessment
scoring system7 when they fulfill the following criteria (a) recent ascent in
altitude, (b) have a headache, and (c) have a total symptom score above 3
Symptoms:
1. Headache:
No headache 0
Mild headache 1
Moderate headache 2
Severe, incapacitating 3
2. GI symptoms:
No GI symptoms 0
Poor appetite or nausea 1
Moderate nausea or vomiting 2
Severe nausea and vomiting incapacitating 3
3. Fatigue/weak:
Not tired or weak 0
Mild fatigue/weakness 1
Moderate fatigue/weakness 2
Severe fatigue/weakness, incapacitating 3
4. Dizzy/lightheadedness:
Not dizzy 0
Mild dizziness 1
Moderate dizziness 2
Severe, incapacitating 3
5. Difficulty sleeping:
Slept well as usual 0
Did not sleep as well as usual 1
Woke many times, poor night's sleep 2
Could not sleep at all 3
Total symptom score:
Clinical assessment:
6. Change in mental status:
No change 0
Lethargy/lassitude 1
Disoriented/confused 2
Stupor/semiconsciousness 3
7. Ataxia(heel to toe walking):
No ataxia 0
Maneuvers to maintain balance 1
Steps off line 2
Falls down 3
Can't stand 4
8. Peripheral edema:
No edema 0
One location 1
Two or more locations 2
Clinical assessment score:
Total score:
An additional clinical assessment scoring is sometimes used.
GI indicates gastrointestinal.
468 C. Imray et al. / Progress in Cardiovascular Diseases 52 (2010) 467–484
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2.3 Pulse oximetry  
Resting SaO2 was measured in subjects using a pulse oximeter (MCDEI 8500M, Nonin 
Medical Inc, Plymouth, MN). Pulse oximetry presents a rapid and non-invasive method 
for assessing SaO2 in a remote environment but their accuracy is reduced at lower SaO2 
(147). Previous studies have demonstrated that in healthy volunteers, oximeters 
commonly have a mean difference (bias) of <2% and a standard deviation (precision) of 
< 3% when SaO2 is 90% or above (148). Accuracy of pulse oximeters deteriorates 
when SaO2 falls to 80% or less. In healthy volunteers under hypoxic conditions, bias of 
pulse oximetry using other similar devices varies from –15.0 to 13.1% while the 
precision ranges from 1.0 to 16.0% (147, 149).  
Bias and precision data for the Nonin MCDEI 8500M pulse oximeter is not published, 
but the manufacturers state, through personal correspondence, that the device is 
accuracy tested by induced hypoxia studies on healthy subjects in an independent 
research laboratory over the SaO2 range of 70 - 100% (all SaO2 values recorded in this 
study fall within this range). In these tests, the SaO2 measured by the pulse oximeter is 
compared to arterial haemoglobin oxygen value, determined from blood samples with a 
laboratory co-oximeter. Accuracy data in these tests are calculated using the root-mean-
squared (Arms value) and the pulse oximeter used in these studies conforms to the 
standards of ISO 9919:2005, Medical Electrical Equipment–Particular requirements for 
the basic safety and essential performance of pulse oximeter equipment for medical use 
(150).  
To minimize the influence of movement, exertion and perfusion that may influence the 
accuracy of pulse oximeters (149), the measurement of SaO2 was standardised in this 
study. SaO2 was recorded in resting subjects in the sitting position and the pulse 
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oximeter was applied to the index finger. The accuracy of a finger probe, such as that 
used in this study exceeds the use of probes on other anatomical sites such as the ear 
lobe, forehead or nose (151). Digits were pre-warmed to avoid poor pulse signals due to 
low perfusion. SaO2 values were accepted when the device displayed a stable result for 
several seconds. 
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CHAPTER 3: ACE I/D and Ascent to Extreme High Altitude 
 
3.1 Background 
3.2 Methods 
3.2.1 Ethics 
3.2.2 Subjects  
3.2.3 Subject Data 
3.2.4 Genetic Analysis 
3.2.5 Statistical Analysis 
3.3 Results 
3.4 Discussion 
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The data from this chapter have appeared in peer-reviewed published form, as:  
Julian Thompson, James Raitt, Lynn Hutchings, Fotios Drenos, Eirik Bjargo, Are Loset, 
Mike Grocott and Hugh Montgomery for the Caudwell Xtreme Everest Research 
Group. Angiotensin-converting enzyme genotype and successful ascent to extreme high 
altitude. High Altitude Medicine and Biology. Volume 8, Number 4, 2007, Pages 278-
285. 
 
3.1 Background 
When this study was conceived in 2005, the ACE I-allele had been associated with elite 
endurance performance and was overrepresented in 25 elite high altitude mountaineers 
who had climbed regularly to over 7000m (86). Although a second study had confirmed 
this finding at moderate altitude (110), no further studies had tested the hypothesis that 
the ACE I-allele is associated with successful physical performance in the hypobaric 
hypoxic environment of extreme high altitude.  
 
If the I-allele is indeed associated with enhanced performance in hypoxic environments, 
then the I-allele ought to be over-represented amongst those successful in ascending the 
very highest peaks - those of 8000 metres standing or above. I sought to test this 
hypothesis. 
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3.2 Methods 
3.2.1 Ethics 
The study was approved by the Joint UCL/UCLH Ethics Committee. Written informed 
consent was obtained from all study participants.  
 
3.2.2 Subjects  
Subjects were high altitude mountaineers who were participating in an expedition to 
climb one of the fourteen 8000m peaks in the world. I recruited participants at Everest 
North Side Base Camp, Tibet, China and mountaineers contacted through expedition 
organisers, mountaineering clubs, professional mountaineering associations and 
advertisements on mountaineering websites.  No local mountaineering porters or guides 
were included in the study as their success or failure in reaching the summit of a 
mountain is frequently dependent upon the altitude reached by their client rather than 
their own ability. 
 
3.2.3 Subject Data 
Subjects were asked, either in person or by email, to complete a questionnaire of 
demographic data and high altitude history mountaineering experience (Questionnaire: 
Appendix 1). Following the attempt to climb an 8000m peak, self-reported maximum 
altitude reached, oxygen use, and reason for failed ascent (where appropriate) were 
recorded. Self-reported data were cross-referenced with the Himalayan Database 
(www.himalayandatabase.com) for consistency and peer confirmation. 
 
 
 
   49 
3.2.4 Genetic Analysis 
For those who consented to take part, DNA was collected using a buccal swab and was 
genotyped for ACE I/D polymorphism (see Chapter 2: Method and Materials for 
details). 
 
3.2.5 Statistical Analysis 
Genotype-dependent differences in high altitude performance were assessed by Chi-
squared testing, Fisher’s exact test and one-way ANOVA as appropriate. The influence 
of age, gender, race and ACE genotype on reaching 8000 metres were tested using 
binary logistic regression analysis.  The level of statistical significance was set for 
P≤0.05.  
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3.3 Results  
ACE genotyping failed in two of the 141 subjects initially recruited. Of the remaining 
139, 125 were male and 14 female. One hundred and nine subjects were Caucasian and 
30 were South Asian (28 Indian, 1 Nepalese and 1 Bhutanese). Age, weight and height 
data were available for 112: mean + sd age was 39.7 + 9.5 years, mean height 175.6 + 
8.7 cm and weight 73.9 + 10.1 kg. ACE genotype distribution was 33 (23.7%) vs 69 
(49.6%) vs 37 (26.5%) for II vs ID vs DD respectively (I-allele frequency 0.49), and 
was consistent with Hardy Weinberg Equilibrium. Demographic data were independent 
of genotype. 
 
Twelve individuals (8.6%) reported episodes of High Altitude Cerebral Edema (HACE) 
or High Altitude Pulmonary Edema (HAPE) in their past climbing history. A past 
history of HAPE or HACE was not associated with ACE genotype (Fisher’s exact test 
p=0.419).  
 
Table 3.1 ACE I/D genotype and mean maximum altitude achieved 
ACE genotype Maximum altitude achieved 
II 8559 + 565m 
ID 8107 + 653m 
DD 8079 + 947m 
Mean maximum altitude in metres + standard deviation. 
 
The maximal altitude achieved varied considerably, with a range of 4800-8848m, mean 
8206.71 + 747m, but was consistently associated with the I-allele (F=5.112, df=2, 
p<0.002) (Table 3.1). ACE genotype distribution differed significantly between those 
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who successfully climbed beyond 8000m, and those who had failed in the attempt 
(χ2=11.894, df = 2, p=0.003; Fisher’s exact test p=0.001), with a relative over-
representation of the I-allele amongst the successful group (0.55 vs 0.36 in successful vs 
unsuccessful respectively). Overall, 32.6% (30) of individuals in the ‘successful’ group 
were of II genotype, but only 6% (3) in the ‘unsuccessful’ group (Table 3.2).  
 
Table 3.2 ACE I/D genotype and success in ascent to 8000 metres. 
 Climbed >8000m Not climbed >8000m Total 
II 30 (32.6%) 3 (6.4%) 33 (23.7%) 
ID 41 (44.6%) 28 (59.6%) 69 (49.6%) 
DD 21 (22.8%) 16 (34.0%) 37 (26.6%) 
I allele frequency 0.55 0.36 0.49 
D allele frequency 0.45 0.64 0.51 
Values are numbers of individuals (percentage of Group in brackets). 
 
 
Figure 3.1 ACE I/D genotype distribution and success in 139 mountaineers attempting 
to climb beyond 8000 m 
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In the group who had successfully climbed to over 8000m, there was no statistical 
difference in ACE genotype frequency between those who climbed to over 8000m using 
oxygen and those who did not use oxygen (23 [34.8%] II, 26 [39.4%] ID, 17 [25.8%] 
DD vs 7 [26.9%], 15 [57.7%] and 4 [15.4%] respectively; χ2=2.640, df = 2, p=0.267). 
 
Caution must be taken in the interpretation of data relating to samples in which race is 
mixed, given that genotype distributions may differ. Here, ACE genotype distribution 
was similar to those previously published (152), being 20 (18.3%) II, 56 (51.4%) ID and 
33 (30.3%) DD for Caucasians, and 13 (43.3%), 13 (43.3%) and 4 (13.3%) respectively 
for South Asians (χ2=9.029, df = 2, p=0.011), with the I allele being overrepresented 
amongst the South Asian group (0.65 vs 0.44 respectively). However, such differences 
in genotype distribution between races could not have accounted for our findings: 
success at climbing to over 8000m was independent of race (66% of the Caucasian 
group and 67% of the South Asian groups successfully reaching this altitude (χ2=0.004, 
df = 1, p=0.950).  Further, when the two racial groups are analysed independently, the I-
allele remained significantly associated with success in climbing to 8000 metres in the 
Caucasian group (Fisher’s exact test p=0.032) and in the South Asian group (Fisher’s 
exact test p=0.003). 
 
Logistic regression analysis demonstrated a strongly significant association between 
reaching 8000 metres and the I-allele (Exp (B) = 8.554, p=0.002). None of the other 
confounding variables in the regression analysis were significantly associated with high 
altitude success, including age or race (Table 3.3).  
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Table 3.3: Logistic regression analysis of the categorical variables influencing success 
in ascent to 8000 metres. 
 
 P value 
Age 0.620 
Sex 0.184 
Race 0.118 
ACE I-allele 0.002 
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3.4 Discussion 
This study demonstrates an association between the ACE I-allele and successful ascent 
to 8000m. At the time of publication this study was the first to confirm an association 
between elite high altitude performance and the ACE I-allele following the observation 
in a small number of elite British mountaineers (86).  
This finding accords with studies that have demonstrated an association of the I-allele 
with prospective success in ascent of Mt. Blanc (4807 m)(110) and an increased I-allele 
frequency in high altitude residents in the Andes (138) and Himalayas (140).  
As discussed in Chapter 1, several mechanisms have been proposed to underlie this 
association. Falling plasma aldosterone levels at altitude encourage natriuresis and 
diuresis, thus reducing the propensity to edema and possibly to acute mountain sickness 
(79). One might postulate that the D-allele, being associated with higher ACE activity, 
may inhibit this protective fall in aldosterone levels and increase the development of 
AMS. The association of ACE I/D and AMS is further explored in Chapter 4. 
The I-allele has been associated with an enhanced ventilatory response to exertional 
hypoxia (112), which may result in better-maintained arterial oxygenation during rapid 
ascent to high altitude (111). However, against this supposition, arterial oxygen 
saturation seems independent of genotype when ascents are more graded (111), as is 
likely to be the case on ascents to 8000m and above.  
The D-allele may be associated with an exaggerated hypoxic pulmonary 
vasoconstriction response and HAPE (129). The incidence of diagnosed HAPE reported 
in this study was low and seems unlikely to have accounted for success or failure in 
reaching 8000 m. However, it remains possible that increased pulmonary vascular 
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resistance or low-grade pulmonary edema may yet have accounted for the genotype 
dependence of success or its lack. Certainly, angiotensin II, generated by ACE activity, 
increases vascular permeability and might thus increase V/Q mismatch and offer a 
diffusion barrier to oxygen transport (153, 154). If the I-allele advantage is mediated by 
either of the mechanism of an altered ventilatory response or reduced diffusion barrier 
to oxygen transport it would be expected that the I-allele would be associated with 
enhanced oxygen saturations at high altitude. This is further investigated in Chapter 5.  
Caution must be taken in studies such as this to identify possible confounding variables. 
The use of supplementary oxygen at extreme altitude is common and is generally 
regarded as an important determinant of success. This study demonstrated no significant 
difference in ACE I/D genotype between those who have climbed to above 8000m with 
or without the use of supplementary oxygen. This may be due to the number of climbers 
who successfully climbed above 8000m without oxygen being too small to demonstrate 
a difference. However, all mountaineers attempting to climb to 8000m spend several 
weeks at high altitude acclimatising to hypoxia. 
Race was not associated with success in climbing to over 8000 m. Therefore, despite the 
difference in ACE genotype distribution in the Caucasian and South Asian groups seen 
in this and other studies (155), the inclusion of different racial groups in the study does 
not account for the increased frequency of the I-allele in the successful mountaineer 
group. Additionally, if the Caucasian group is addressed alone, the association of the I-
allele with success remains. 
Conclusions 
This study demonstrates that the ACE I-allele is associated with successful ascent to 
8000m.  
   56 
 
CHAPTER 4: ACE I/D genotype and Susceptibility to Acute Mountain Sickness 
(AMS) 
4.1 Background 
4.2 Study 1: ACE I/D and AMS in trekkers on Mt. Kilimanjaro (5895m) 
4.2.1 Methods 
4.2.1.1 Ethics 
4.2.1.2 Subjects 
4.2.1.3 Subject data 
4.2.1.4 Genetic analysis 
4.2.1.5 Statistical analysis 
4.2.2 Results 
4.3 Study 2: ACE I/D and AMS in trekkers at 4300m on Cerro Aconcagua (6963m) 
4.3.1 Methods 
4.3.1.1 Ethics 
4.3.1.2 Subjects  
4.3.1.3 Subject data 
4.3.1.4 Genetic Analysis 
4.3.1.5 Statistical Analysis 
4.3.2 Results 
4.4 Discussion 
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Data from this chapter have appeared in peer-reviewed published form, as: 
NS Kalson, J Thompson, AJ Davies, MD Earl, S Stokes, AG Whitehead, I Tyrell-
Marsh, H Frost, H Montgomery. The effect of the ACE I/D polymorphism on acute 
mountain sickness and summit success in trekkers attempting the summit of Mt 
Kilimanjaro (5895m). European Journal of Applied Physiology. 2009 Feb;105(3):373-
379. 
 
4.1 Background 
ACE I/D polymorphism is associated with enhanced performance in hypoxic 
environments (107, 110, 156) but conflicting data existed regarding whether this 
enhanced performance is mediated by an association between the ACE I/D 
polymorphism and susceptibility to AMS (110, 123).  
 
If resistance to AMS mediates the performance advantage at high altitude associated 
with the I-allele, then the I-allele should be associated with lower incidence and severity 
of AMS in those exposed to hypobaric hypoxia. I undertook 2 prospective studies to test 
the hypothesis that the ACE I-allele confers resistance to AMS. 
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4.2 Study 1: ACE I/D and AMS in trekkers on Mt. Kilimanjaro (5895m) 
 
Mount Kilimanjaro (5895m) is the highest peak on the African continent and, as a 
volcano arising from lowland plains, is the highest free-standing mountain in the world. 
This status and the ease of ascent make it an attractive destination for trekkers. The 
geography of the mountain means that those who aspire to climb the mountain are 
largely altitude naïve and a combination of national park regulations and the 
commercial nature of expeditions to this mountain ensure that trekkers are required to 
participate in 4 or 5 day ascents from 2700m to the summit (5895m). These factors 
result in an incidence of AMS of up to 86% in those attempting to reach the summit 
(157). This study set out to recruit a large prospective cohort attempting to trek to high 
altitude on Mount Kilimanjaro (5895m), Tanzania with the aim of testing the hypothesis 
that the ACE I allele confers resistance to AMS.  
 
The sample and data collection on Mount Kilimanjaro was undertaken by Manchester 
University undergraduate medical students.  I collaborated with this team on study 
design, logistics, genotyping, data interpretation and writing up of this study. 
 
4.2.1 Methods 
 
4.2.1.1 Ethics 
 
The study was approved by the Joint UCL/UCLH Ethics Committee. Written informed 
consent was obtained from all study participants. Additional approval was achieved 
from the Tanzanian National Institute for Medical Research, the Tanzanian Commission 
for Science and Technology (2005-261-NA-2005-62) and the Tanzanian National Parks 
Authority. 
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4.2.1.2 Subjects  
Subjects comprised Caucasian tourist trekkers attempting to reach the summit of Mount 
Kilimanjaro (5895m) in Tanzania. Excluded were those exposed to altitudes >3000m in 
the past two weeks, those taking steroids or acetazolamide for AMS prophylaxis, those 
taking RAS antagonists (ACE inhibitors, or angiotensin II type 1 receptor antagonists) 
or those using supplemental oxygen.  
All ascended by the Marango route, upon which subjects stay at fixed huts on their 
ascent: all stay for one night at 2700m, 3700m and 4700m, and some have an extra 
(second) overnight stop at 3700m. All then attempted the summit (5895m), and stopped 
at 3700m on descent. Researchers were stationed on the mountain at each of the three 
huts.  
 
4.2.1.3 Subject data 
All trekkers attempting the summit were asked to take part in the study at the first hut 
on their ascent (2700m).  Written informed consent was obtained, as was a buccal swab 
to permit genetic analysis. Subjects were asked to report to a researcher each evening 
while on the mountain, during both ascent and descent, when the presence of AMS and 
its severity was determined using the Lake Louise Score (Table 1.3). As used by others, 
a score of >4 was used to define the presence of AMS (116, 118). AMS on the summit 
day was determined retrospectively at 4700m on descent.  
 
4.2.1.3 Genetic analysis 
For those who consented to take part, DNA was collected using a buccal swab and was 
genotyped for ACE I/D polymorphism (see Chapter 2: Methods for details). 
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4.2.1.4 Statistical analysis 
Results were analysed using SPSS version 14. Chi squared test was used to confirm 
Hardy-Weinberg equilibrium. Differences in study population physiological parameters 
were assessed by ANOVA or Chi squared testing as appropriate. Differences between 
genotype groups for AMS incidence and severity were sought using chi squared or 
analysis of variance on ranks (Kruskal-Wallis). Differences in summiting success were 
tested using Fisher’s exact test or chi squared as appropriate. Throughout, a p-value 
≤0.05 was considered statistically significant. Normally distributed data are presented as 
mean + SD, and non-normal data as median (range). As greater speed of ascent is 
strongly associated with development of AMS, the two cohorts with different ascent 
profiles were, a priori, analysed separately.  
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4.2.2 Results  
During the study period, 343 subjects were approached of whom 56 declined to take 
part, 79 were taking prophylactic acetazolamide, and 32 were not altitude-naïve. This 
left a study population of 173 individuals (104 male), whose ACE genotype distribution 
was consistent with Hardy-Weinberg equilibrium (38 II, 91 ID, 43 DD, p = 0.556), and 
whose physical characteristics (height 173 + 10 cm, weight 69.7 + 13.5 kg, age 35.8 + 
11.6 years) were independent of ACE genotype.  
Some fifty-seven subjects (34 male) were lost to follow-up during the study (likely due 
to non-communicated withdrawal from the study, or elective descent due to discomfort 
or illness) whose physical characteristics (height 1.74 + 0.11 m, weight 69.9 + 13.1 kg, 
age 35.2 + 11.5 years) and ACE genotype distribution (14 II [24.6%], 30 ID [52.6%], 13 
DD [22.8%]) did not differ from those followed up (24 II [20.7%], 61 ID [52.6%], 31 
DD [26.7%], p = 0.45 – 0.914).  
From 2700m, all subjects spent one night at 3700m (n=165). Of these, 107 spent an 
extra night at 3700 to aid acclimatisation (acclimatisation profile – A), whilst 42 
continued to 4700 m (direct profile – D). Of the 107 attempting the summit via the 
acclimatisation profile (A), 92 were followed up at 4700m, then 82 on their summit 
attempt (Figure 4.1). Of these, 41 reached the summit. Of the 42 attempting the summit 
via the direct profile (D) 34 were followed up on their summit attempt, 20 of whom 
reached the summit. The physical characteristics (sex, height, weight and age) of those 
on route A did not differ from those on route D. However, there was an excess of ID 
genotype in the direct ascent group when compared with the A ascent group (7 II 
[12.2%], 38 ID [66.6%], 12 DD [21.0%] versus 29 II [27.1%], 48 ID [44.9%], 30 DD 
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[28.0%] respectively p = 0.02:  I-allele frequency 0.46 in those on route D compared 
with 0.50 for those on route A, table 4.1).  
 
Figure 4.1 Schematic diagram of subject progression up Mt. Kilimanjaro showing ACE 
genotype distribution of subjects followed-up during the study  
 
 
 
 
2700m    n= 173 
(38 II, 99 ID, 44 DD) 
3700m   n = 165 
(36 II, 87 ID, 42 DD) 
 
3700m (A) 
n=107 (29 II, 48 ID, 30 DD) 
4700m (D) 
n=42 (6 II, 27 ID, 9 DD) 
4700m (A)  
n = 99 (26 II, 46 ID, 27 DD) 
Summit attempt (D) 
n=34 (6 II, 21 ID, 7 DD) 
Summit attempt (A)    
n=82 (18 II, 40 ID, 24 DD) 
Day 1 
Day 2 
Day 3 
Day 4 
Day 5 
Summit success (A)     
n=41 (9 II, 18 ID, 14 DD) 
Summit success (D) 
n=20 (6 II, 11ID, 3 DD)  
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Table 4.1 Genotype frequencies in those completing the study and those dropping out 
for each altitude on ascent of Mt Kilimanjaro  
 2700m 3700m (D) 3700m (A) 4700m (D) 4700m (A) Summit (D) Summit (A) 
 II ID DD II ID DD II ID DD II ID DD II ID DD II ID DD II ID DD 
Recorded 38 91 44 7 38 12 29 48 30 6 27 9 26 46 27 6 21 7 18 40 24 
Total 173 57 107 42 99 34 82 
Drop-out 0 0 0 0 0 0 0 0 0 1 11 3 3 2 3 0 6 2 8 6 3 
Total 0 0 0 15 8 8 17 
(D) = Direct, (A) = Acclimatisation night at 3700m 
Total dropping out during the study = 57 (14 II, 30 ID, 13 DD, I-allele frequency 0.51) 
Total completing the study = 116 (24 II, 61 ID, 31 DD, I-allele frequency 0.47), p =0.49) 
Total ascending by direct route (D) = 57 (7 II, 38 ID, 12 DD, I-allele frequency 0.46) 
Total ascending by acclimatisation route (A) = 107 (29 II, 48 ID, 30 DD, I-allele frequency 0.50 p = 0.02) 
 
ACE genotype was not associated with presence of AMS per se at any altitude (Table 
4.2). On arrival at most altitudes, there was a suggestion that AMS scores rose with 
increasing D-allele frequency. However, at no point did this reach statistical 
significance (Table 4.3). 
 
Table 4.2 AMS presence, defined as LLS ≥4, in subjects on the Direct and 
Acclimatisation profiles stratified according to ACE genotype 
    2700m 3700m 
3700m 
(Acclimatisation 
night) 
4700m (D) 4700m (A) Summit (D) 
Summit 
(A) 
ACE 
Genotype  II ID DD II ID DD II ID DD II ID DD II ID DD II ID DD II ID DD 
AMS 
presence  
Yes  0 0 1 5 9 6 4 10 8 2 13 7 9 19 13 5 19 6 12 32 15 
No 38 91 43 31 78 36 25 38 22 4 14 2 17 27 14 1 2 1 6 8 9 
  Total  173 165 107 42 99 34 82 
  p = 0.23 0.76 0.47 0.18 0.61 0.87 0.27 
(D = direct ascent profile, A = acclimatisation profile) 
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Table 4.3 AMS severity (mean Lake Louise Score) in subjects on the Direct and 
Acclimatisation profiles stratified according to ACE genotype  
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At no altitude were AMS scores different between those dropping out and those 
followed-up (p=0.43-0.87).  
 
There was no significant association between ACE genotype and successful ascent to 
the summit (Table 4.4) and, interestingly, there was no significant association between 
summit success and AMS presence at 4700m or on the summit attempt in either the 
Acclimatisation or Direct groups (p = 0.09 – 1.00, Table 4.5).  
 
Table 4.4 Summit success in subjects on the Direct and Acclimatisation profiles 
stratified according to genotype  
 
 
Table 4.5 Summit success versus AMS presence (defined as LLS ≥4) in subjects on the 
Direct and Acclimatisation profiles  
  
AMS presence 
4700m (A)  4700m (D)  Summit Day (A) Summit Day (D) 
No Yes  No Yes  No Yes  No Yes  
Summit    
Success 
Yes 26 15 41 12 8 20 15 26 41 2 18 20 
No 20 21 41 7 7 14 8 33 41 2 12 14 
Total 46 36 82 19 15 34 23 59 82 4 30 34 
 p = 0.18 p = 0.73 p = 0.09 p = 1.00  
% success 
rate
% success 
rate
Y No Total Y No Total
II 9 9 18 50 6 0 6 100
ID 18 22 40 45 11 10 21 52
DD 14 10 24 58 3 4 7 43
41 41 82 50 20 14 34 59
p = 0.54 p = 0.09
Summit Success
Acclimatization route (A) Direct route (D)
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4.3 Study 2: ACE I/D and AMS in trekkers at 4300m on Cerro Aconcagua 
(6959m) 
 
Cerro Aconcagua (6959m), Argentina is the highest peak on the continent of South 
America and this status and the ease of ascent make it an attractive destination for 
trekkers. This study set out to recruit a large prospective cohort attempting to climb to 
the summit of Cerro Aconcagua (6959m) with the aim of testing the hypothesis that the 
ACE I-allele confers resistance to AMS. 
The sample and data collection on Cerro Aconcagua, Argentina was undertaken by 
medical students from the Norwegian University of Science and Technology, 
Trondheim, Norway. I collaborated with this team on study design, logistics, 
genotyping, data interpretation and writing up of this study. 
 
4.3.1 Methods 
4.3.1.1 Ethics 
 
The study was approved by the Joint UCL/UCLH Ethics Committee. Written informed 
consent was obtained from all study participants. Additional approval was obtained 
from the Regional Ethical Committee of Mid-Norway, the Norwegian Biobank 
Committee and the Norwegian Data Inspectorate.  
 
4.3.1.2 Subjects  
Subjects were Caucasian trekkers attempting to climb Cerro Aconcagua (6959m) and 
were recruited at Plaza de Mulas base camp (4300m). This base camp is reached by a 2-
3 day approach via an intermediate camp at 3100m. Trekkers attempting to climb Cerro 
Aconcagua are required to register with the Park Rangers of Aconcagua Park on arrival 
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at base camp. The investigators were based at the rangers’ hut where registration occurs 
with the aim of recruiting subjects on arrival to altitude. Excluded were those who had 
spent more than 48 hours at 4300m, those taking steroids or acetazolamide for AMS 
prophylaxis and those taking RAS antagonists (ACE inhibitors, or angiotensin II type 1 
receptor antagonists).  
4.3.1.3 Subject data 
Subjects completed a questionnaire (in English or Spanish), and written informed 
consent was obtained from all volunteers. Age, sex, height, weight, duration of stay, 
medical history and recent medication were documented (Appendix 2). Presence and 
severity of current AMS symptoms were documented using the Lake Louise Score 
(LLS) (Table 4.1). As used by others, a score of >4 was used to define the presence of 
AMS (118). Success or failure in reaching the summit of Cerro Aconcagua (6959m) 
was self reported by the subjects as they returned to record their safe return to Base 
Camp with the Aconcagua Park Rangers.  
4.3.1.4 Genetic Analysis 
For those who consented to take part, DNA was collected using a buccal swab and was 
genotyped for ACE I/D polymorphism (see Chapter 2: Methods for details). 
4.3.1.5 Statistical Analysis 
Results were analysed using SPSS version 21. Chi squared test was used to confirm 
Hardy-Weinberg equilibrium. Differences in study population physiological parameters 
and genotype groups for AMS incidence and severity were assessed by ANOVA or Chi 
squared testing as appropriate. Throughout, a p-value ≤0.05 was considered statistically 
significant.  
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4.3.2 Results  
During the study period, 110 (89 male) Caucasian subjects were recruited. ACE 
genotyping failed in two of the 110 subjects and in the remaining subjects genotype 
distribution was 23 (21%) versus 44 (41%) versus 41 (38%) for II versus ID versus DD, 
respectively (I-allele frequency 0.417), consistent with the Hardy-Weinberg 
equilibrium. In this cohort, physical characteristics (height 177.8 + 9 cm, weight 74.5 + 
11 kg, age 35.2 + 10.5 years) were independent of ACE genotype. At the time of 
assessment, the mean +/- SD duration of stay at 4300m had been 22.6 + 9.1 hours and 
there was no association with duration of stay and ACE genotype (p=0.394). 
 
AMS and LLS 
LLS was assessed in all subjects and the mean + SD LLS was 2.2+1.8.  AMS symptoms 
and clinical assessments are illustrated in Figures 4.3, 4.4 and 4.5. LLS score was not 
associated with age, sex, weight, height or with duration of time at 4300m prior to 
assessment. 
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Figure 4.3 AMS Symptoms at 4300m 
 
 
 
Figure 4.4 AMS Clinical Assessment at 4300m 
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Figure 4.5 Lake Louise Scores at 4300m 
 
 
 
 
AMS score and ACE genotype 
AMS scores by genotype are displayed in Table 4.7. Mean + SD AMS LLS by ACE 
genotype was 2.35+1.87, 2.091+1.78 and 2.195+1.0 for II, ID and DD respectively. 
There was no significant association between ACE I/D genotype and total LLS 
(p=0.858) or LLS symptom score (p=0.875) (Figure 4.6). 
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Table 4.6 ACE I/D genotype and LLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 ACE I/D genotype and LLS 
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 p=0.858  
   72 
AMS presence and ACE genotype 
Using a LLS ≥4 to define the presence of AMS, 22 of the 110 subjects (20%) suffered 
from AMS at the time of assessment. Genotype distribution for those suffering from 
AMS was 7 (32%) vs 8 (36%) vs 7 (32%) (I allele frequency 0.5) and for those who did 
not suffer, 16 (19%) vs 36 (42%) vs 34 (39%) (I allele frequency 0.395) for II vs ID vs 
DD genotype respectively. There was no association between ACE genotype and the 
presence of AMS (p=0.406). Interestingly 30% of the ACE II subjects suffered from 
AMS by comparison with 18% and 17% of the ID and DD subjects respectively, but 
this did not reach statistical significance (p=0.24). 
Table 4.7 ACE I/D genotype and presence of AMS (LLS ≥4) 
 ACE genotype Total 
II ID DD 
AMS 
No 16 36 34 86 
Yes 7 8 7 22 
AMS presence 30% 18% 17% 20% 
 p=0.406  
 
Successful summit ascent 
Data on success or failure in reaching the summit of Cerro Aconcagua was available on 
104 of the 110 subjects. Sixty-seven subjects with available data were successful in 
reaching the summit. There was no association between summit success and sex, weight 
or height (Table 4.11) although there was a strong association between age and summit 
success (p=0.008) with a mean + SD age of 32.9+8.8 years in those who reached 6963m 
and 38.1+10.8 years in those who did not.  In those who succeeded in reaching the 
summit the mean + SD LLS at assessment was 2.00+1.8 compared to 2.74+1.9 in those 
who failed (p=0.05).  
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Table 4.8 Characteristics of subjects successful in reaching the summit of Cerro 
Aconcagua (data are presented as mean +/- SD) 
 Success  
(68 subjects) 
Failure 
(38 subjects) 
p= 
Age (years) 32.9+8.8 38.1+10.8 0.008 
Sex 84% male 76% male 0.348 
Height (cm) 177.6+9.7 178.3+8.3 0.687 
Weight (kg) 73.5+10.8 77.0+12.3 0.131 
Hours at 4300m 23.1+9.8 21.6+8.1 0.404 
LLS 2.00+1.8 2.74+1.9 0.05 
 
ACE genotype and successful ascent 
ACE genotype distribution for those who succeeded was 15 (22%), 26 (39%) and 26 
(39%) and those who failed 7 (19%), 17 (46%) and 13 (35%) for II, ID and DD 
respectively (Table 4.12). There was no association demonstrated between ACE I/D 
genotype and success in climbing to the summit of Cerro Aconcagua (p=0.99). 
Table 4.12 ACE I/D genotype and success in reaching 6963m. 
 ACE I/D genotype Total 
II ID DD 
Summit 
Success 15 26 26 67 
Failure 7 17 13 37 
Success rate 68% 60% 67% 64% 
 p=0.99  
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4.4 Discussion 
These 2 studies did not demonstrate an association between ACE I/D polymorphism 
and AMS in Caucasian mountaineers at altitudes between 2700m and 5895m on Mount 
Kilimanjaro, Tanzania and at 4300m on Cerro Aconcagua, Argentina. Moreover, the 
ACE I-allele was not associated with successful ascent to the summit of Mt Kilimanjaro 
(5895m) or Cerro Aconcagua (6959m) in the 2 large cohorts of high altitude trekkers 
assessed.  An association between successfully reaching the summit of Cerro 
Aconcagua and younger age and lesser severity of AMS at assessment was 
demonstrated. 
As described previously, while several plausible physiological mechanisms exist by 
which ACE I/D polymorphism may be hypothesized to influence AMS susceptibility, at 
the time of these studies conflicting data existed regarding the association of ACE I/D 
genotype with AMS development (110, 123, 124). Of the 2 other studies addressing this 
question in Caucasian subjects, Dehnert et al. demonstrated no association between the 
ACE I/D polymorphism and AMS susceptibility at 4559m (123) whereas Tsianos et al. 
demonstrated an association between the heterozygous ACE ID genotype and resistance 
to AMS (P=0.003) in 284 climbers assessed on arrival from lower altitude at the Gouter 
Hut (3,807 m), Mt Blanc (110). Subsequent studies have continued to deliver discordant 
results with Buroker et al. comparing the genotype of 98 AMS patients with 60 Han 
controls and finding the ACE D-allele to be significantly associated with AMS (158).  
In 2012, Luo et al. undertook a meta-analysis of the published studies to assess the 
association between the ACE I/D polymorphism and AMS. A fixed effects model was 
applied and study quality was assessed in duplicate. Five studies with a total of 333 
AMS cases and 373 healthy controls were assessed and revealed no significant 
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differences in risk for AMS between ACE I/D genotype (159). This meta-analysis 
included the results of Study 1 (160) but not the currently unpublished results of Study 
2. 
It may be proposed that some of these discordant results reflect the clinical imprecision 
of the diagnosis of AMS and the lack of diagnostic modalities or physical findings to 
reliably confirm the presence of this disease entity (114). The Lake Louise Consensus 
Committee definition of AMS is headache in the setting of recent arrival to high altitude 
and one or more of the following: anorexia, nausea, or vomiting; fatigue or weakness; 
dizziness or lightheadedness; or difficulty sleeping (119). Other diagnostic scoring 
systems also exist with variously reported sensitivity and specificity (118). Furthermore, 
different biological mechanisms may be driving different symptoms independently of 
one another. 
AMS may progress to the life threatening HACE or HAPE and recognition and 
appropriate action is critical (116). However the differential diagnosis of these 
symptoms are broad in typically physically exhausted individuals functioning in austere 
environments. Differential diagnoses may range from the common complaints of 
exhaustion and dehydration to life threatening conditions that may present with similar 
symptoms including carbon monoxide poisoning, central nervous system infection, 
diabetic ketoacidosis, hypothermia, toxins, or viral and bacterial infections (114). 
Clinical examination may help narrow this differential but in larger studies using self 
reporting questionnaires it may be that various disease entities are grouped together and 
that it may be unrealistic to expect a clear association with a single polymorphism. 
Some other points are worthy of note with regard to Study 1 on Mount Kilimanjaro. 
First, both AMS incidence and severity increased with altitude. The higher AMS scores 
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seen in subjects during their acclimatisation day at 3,700 m were likely due to a lag in 
the development of AMS and it is well established that slower ascent rates lead to lower 
incidence of AMS (161). Interestingly there was no difference in AMS scores between 
the subjects who spent an extra day acclimatising at 3,700 m and those who did not; it is 
possible that only one extra day on the mountain does not provide sufficient 
acclimatisation on such a rapid ascent to extreme altitude. 
A strength of Study 1 was the chosen mountain and route. The Marango route on Mt. 
Kilimanjaro was selected because the rapid ascent schedules produce a high incidence 
of AMS and the ascent profile allows researchers to follow subjects at evenly graduated 
intervals on ascent. Additionally the population had little previous acclimatisation; only 
10.2% of screened subjects had visited high altitude in the previous 2 weeks.  
An important limitation of Study 2 was that, whilst subjects were excluded if they had 
spent more than 48 hours at 4300m, the study did not account for the speed of ascent to 
this altitude from sea level and recent history of altitude exposure. Although trekkers 
attempting to climb Aconcagua are principally participants on commercial single peak 
expeditions and guides and porters were excluded from the study, residual 
acclimatisation in some participants could be a confounding variable and subjects with 
different ascent profiles might be expected to be at different points in their 
acclimatisation process.  
The inevitable logistic problems of such fieldwork added to the limitations in both 
studies. In Study 1, 57 subjects (34 male) were lost to follow-up during the study and 
there is a possibility that some of this group descended without presenting to the 
investigators due to AMS. However, this seems an unlikely confounder: the physical 
characteristics and ACE genotype distribution of these individuals did not differ from 
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those followed up, whilst the incidence of AMS and the last recorded AMS scores at 
each altitude were no higher in those lost to follow-up than in those who continued. 
Importantly, AMS scores at any altitude were unrelated to loss to follow-up. AMS 
scores immediately prior to the summit attempt were also independent of both ACE 
genotype and of summit success (Tables 4.2, 4.5). In Study 2, despite the regulation 
requiring trekkers to report to the Aconcagua Park rangers on arrival at 4300m there 
was variation in the time taken for climbers to report and hence to be assessed for this 
study (22.6 + 9.1 hours). Interestingly, the variation in duration of time at 4300m prior 
to assessment was not associated with presence or severity of AMS. With a single 
assessment station at 4300m, Study 2 cannot account for AMS preventing some 
reaching this altitude at all and this may lead to some selection bias. 
The lack of association between the ACE I-allele and successful ascent to the summit of 
Mt Kilimanjaro (5895m) or Cerro Aconcagua (6963m) is perhaps surprising given the 
results of Chapter 3 (156) and previous studies at both lower and higher altitudes (86, 
110, 156).  
It may be that such an association does exist but was not detected in these 2 studies. For 
instance in Study 1, although there was no association demonstrated between ACE 
genotype and AMS or successful ascent, there was a non-significant (p=0.09) trend for 
D-allele association with failure using the most rapid ascent profile. In this group, lack 
of true statistical significance may have been due to powering issues: post-hoc power 
calculations suggest that with the sample size of 34, with 20 successful and 14 
unsuccessful subjects (100% II subjects successful, 52% of ID and 43% of DD, giving 
an effect size of 0.156) the study only had 52% power to detect a difference in summit 
success. Similarly whilst no significance was demonstrated, there was a trend for higher 
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mean AMS scores amongst ID and DD climbers (Table 4.3). This lack of statistical 
significance may again be due to lack of statistical power. The study was underpowered 
to detect a difference—given the difference observed in mean AMS scores between 
genotype groups at 4,700 m on the D route 106 subjects would be needed to achieve 
80% power, rather than this sample of 42 subjects. 
An alternative explanation for the lack of association of the I-allele with summit success 
in these studies may be may be that the populations assessed in these studies on Mt 
Kilimanjaro and Cerro Aconcagua differ from the previous studies of elite mountaineers 
and are representative of a non-elite trekking population. These mountains are not 
technical in nature and thus attract large numbers of amateur trekkers who aspire to 
reach great altitude. These peaks were chosen for exactly this popularity with tourist 
trekkers with the aim of generating large numbers of study participants who were being 
exposed to hypobaric hypoxia. At sea level, elite athletic endurance performance has 
been associated with the I-allele (162-164) but discordant results in groups of mixed 
ability and sporting discipline (90, 165). The diverse challenges and novel skills 
confronting amateur trekkers at altitude may confound the single limiting effect of 
hypobaric hypoxia when compared to experienced and elite high altitude mountaineers 
(86, 156). Moreover, whilst altitudes of up to 6959m do represent a profound 
physiological challenge, they do not approach the cusp of human survival that the 
hypoxia of peaks of 8000m or more present (2). It may be that the effect of the ACE I-
allele becomes more evident at the phenotypic extremes and that the impact is not 
evident at lesser altitudes. However this is not consistent with the findings of Tsianos et 
al. who demonstrated an I-allele association with successful ascent of Mt Blanc at the 
lower altitudes of 4807m (110).  
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Conclusions 
 
The ACE I/D genotype was compared between individuals who did or did not 
develop AMS, as defined by Lake Louise Score (LLS), during the ascent of Mount 
Kilimanjaro (5895m) and after arriving at Plaza de Mulas basecamp (4300m), Cerro 
Aconcagua, Argentina. No association was found between the ACE I/D genotype and 
AMS incidence or severity or success in reaching the summit of either mountain.  
 
The lack of association between ACE I/D genotype and AMS demonstrated in these 
studies suggest that any advantage conferred by the ACE I-allele in previous studies is 
unlikely to be mediated by reduced susceptibility to AMS.  
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CHAPTER 5: ACE I/D Polymorphism and Arterial Oxygen Saturations at 4300m 
 
5.1 Background 
5.2 Methods 
5.2.1 Subjects  
5.2.2 Subject data 
5.2.3 Genetic Analysis 
5.2.4 Statistical Analysis 
5.3 Results 
5.4 Discussion 
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5.1 Background 
 
ACE I/D polymorphism is associated with enhanced performance in hypoxic 
environments (107, 110, 156) but the mechanisms underlying this association remain 
unclear. Prior to this study, previous publications had demonstrated an association 
between the ACE I-allele and improved arterial oxygen saturation (SaO2) at altitude 
(111) and an increased hypoxic ventilatory response in laboratory conditions of hypoxia 
and exercise (112). I thus sought to undertake a large prospective study to test whether 
the ACE I-allele is associated with enhanced tolerance to high altitude as assessed by 
improved SaO2.  
This study was conducted in the same cohort of Caucasian mountaineers attempting to 
climb Cerro Aconcagua described in detail in Chapter 4 Study 2. 
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5.2 Methods 
5.2.1 Subjects  
Subjects were mountaineers attempting to climb Argentina’s Cerro Aconcagua (6963m) 
and were recruited at Plaza de Mulas base camp (4300m). Excluded were those who had 
spent more than 48 hours at 4300m, those taking steroids or acetazolamide for AMS 
prophylaxis, those taking RAS antagonists (ACE inhibitors, or angiotensin II type 1 
receptor antagonists).  
5.2.2 Subject data 
Subjects were asked to complete a questionnaire of demographic data and high altitude 
history mountaineering experience (Appendix 2). A buccal swab was obtained for 
genetic analysis, subjects completed a questionnaire (in English or Spanish), and written 
informed consent was obtained from all volunteers.  
Resting SaO2 was measured in all subjects using a pulse oximeter (MCDEI 8500M, 
Nonin Medical Inc, Plymouth, MN) placed on the index finger. SaO2 was measured 
with the subject in the sitting position and the value accepted when a stable result was 
displayed. Digits were pre-warmed to avoid poor pulse signals due to low perfusion. 
5.2.3 Genetic Analysis 
For those who consented to take part, DNA was collected using a buccal swab and was 
genotyped for ACE I/D polymorphism (see Chapter 2: Methods for details). 
5.2.4 Statistical Analysis 
Results were analysed using SPSS version 21. Differences in study population 
physiological parameters, AMS, summit success and genotype groups were assessed by 
ANOVA, Chi squared or linear regression analysis as appropriate. Throughout, a p-
value ≤0.05 was considered statistically significant.   
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5.3 Results 
During the study period, 110 (89 male) Caucasian subjects were recruited.  SaO2 data 
were available on all subjects and mean+SD SaO2 on assessment at 4300m were 85.2 + 
3.9% (Table 5.1). SaO2 were not associated with age, sex, height or weight and there 
was no significant correlation between SaO2 and hours spent at 4300m prior to 
assessment (r2=0.005). 
Table 5.1 SaO2 at 4300m in 110 Caucasian trekkers 
 
 
SaO2 ACE I/D genotype 
SaO2 by ACE genotype were 85.8 ± 3.3 %, 85.5 ± 4.2 %, and 84.4 ± 3.9 % for II, ID 
and DD respectively and no significant association was demonstrated (p=0.284). 
 
SaO2 and AMS 
There was a strong association between SaO2 and LLS score (p=0.009). If a LLS≥4 was 
used to define AMS presence the mean+SD SaO2 in those who were suffering from 
AMS was 83.7+3.1% and in those did not have AMS, 85.5+4.0% (p=0.021). 
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SaO2 and summit success 
In those who succeeded in reaching the summit the mean+SD SaO2 at assessment was 
85.1+4.0 compared to 85.4+3.9 (p=0.65) in those who failed. 
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5.4 Discussion 
This study did not demonstrate an association between resting SaO2 and ACE I/D 
genotype or summit success in subjects assessed at 4300m on Cerro Aconcagua. 
However it did identify an association of resting SaO2 with AMS presence and Lake 
Louise Score when assessed at 22.6 + 9.1 hours following arrival at this altitude. 
 
Previously the ACE I-allele has been associated with an enhanced ventilatory response 
to exertional hypoxia (112) and better-maintained arterial oxygenation during rapid 
ascent to high altitude (111). In support, the I-allele is more prevalent, and SaO2 higher, 
amongst highlanders (rather than lowlanders) living in Ladakh (140).  
Patel el al. exposed subjects to a fractional inspired oxygen concentration (FiO2) of 
0.125 during exertion in the laboratory and showed that the hypoxia-induced rise in 
exertional minute ventilation was significantly greater among those of II genotype 
(39.6+/-4.1% versus 27.9+/-2.0% versus 28.4+/-2.2% for II versus ID versus DD, 
respectively). However, similarly to the results in this study on Aconcagua, this 
laboratory study did not show a significant association of ACE genotype with SaO2. 
Conversely, Woods et al. measured SaO2 over many days in trekkers ascending to over 
5000m in the Himalaya. Subjects of ACE II genotype who ascended to above 5000 m in 
12 days were able to maintain higher SaO2, especially as altitude increased. A similar 
trend was evident, but not significant, in a slower ascent group who trekked over 18.5 
days (111). An explanation for this discordance between the two rate of ascent groups 
was proposed that the I-allele benefit is short lived and more important during early-
stage acclimatisation to high altitude. According to Woods et al., this could be due to 
the normalization of the plasma aldosterone concentration to plasma renin activity ratio 
(PAC/PRA) that occurs after 12 to 20 days at high altitude.  
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More recently Bigham et al demonstrated an association of ACE II genotype with 
higher resting and submaximal exercise SaO2 in two groups of Peruvians, one high 
altitude residents and one lowland residents, who were tested at 4338 m altitude (p =
0.008). In both study groups, individuals of ACE II genotype maintained a ~2.3 
percentage point higher SaO2, explaining about 4% of the total variance in resting and 
exercise values (122). This study suggests that the I-allele effect on increasing SaO2 is 
present in high altitude residents and is therefore not an acclimatisation or short-lived 
phenomenon. There is known to be a significant genetic influence upon SaO2 in high 
altitude residents (111, 140, 166, 167) and previous studies have suggested a role for the 
ACE I/D polymorphism (140). 
Proposed mechanisms underlying the ACE I-allele influence have included the 
increased HVR (hypoxic ventilatory response, by which hypoxia stimulates a rise in 
minute ventilation) to increase SaO2 (112) and which is supported by animal studies that 
have shown that the peripheral chemoreceptors contain angiotensin receptors with 
potential effects on the regulation of ventilation (74, 168). Bigham et al. did not find an 
ACE I-allele associated with HVR and speculated that the explanation may be another 
central cardiopulmonary effect of the ACE gene, such as angiotensin II modulating 
hypoxia-induced pulmonary vasoconstriction (70) or differences in circulating ACE 
affecting ventilation–perfusion (V/Q) relationships within the lung (130). 
The lack of association between the ACE I-allele and increased SaO2 seen in this study 
accords with Patel et al. (112) but not with the 2 other studies addressing this issue (111, 
122). This study accounts for time spent at 4300m, but not for the speed of ascent to this 
altitude from sea level and recent history of altitude exposure. Residual acclimatisation 
in some mountaineers could be a confounding variable and mountaineers with different 
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speeds of ascent profile might be expected to be at different points in their 
acclimatisation process. The hypoxic ventilatory response (HVR) increases as part of 
the process of acclimatisation to altitude. As a result, SaO2 increases progressively with 
acclimatisation (169). Despite the probable uniformity imposed by commercial 
expeditions on Cerro Aconcagua, this study could not control for and did not record the 
ascent profile prior to arrival at 4300m. Following arrival there was a delay and 
variance in the time of assessment and recording of SaO2. Although there was no 
association between either ACE I and duration of time spent at 4300m or between 
duration of time spent at 4300m prior to assessment and SaO2 in this study, this potential 
variability in acclimatisation is an important confounding factor. 
In this study it is confirmed that there is a significant association between both 
increasing AMS score and AMS incidence, and reduced SaO2. This finding confirms the 
recognised relationship between AMS and hypoxemia (79, 170-172) and concords with 
previous studies (171, 173) that demonstrated that noninvasive pulse oximetry 
saturations are inversely correlated with the severity of AMS and may detect 
exaggerated hypoxemia in severe AMS (171). 
A potential limitation in this study may be that the use of pulse oximetry in cold 
environments, at altitude and in patients with severe hypoxia may cause inaccurate 
recordings. To minimise the effect of cold, digits were warmed to avoid poor pulse 
signals due to low perfusion. However, pulse oximetry calibration inaccuracy increases 
below 80% and with 8 subject recording SaO2 below this threshold, there may be some 
uncertainty in the accuracy of these lowest values. 
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Conclusion 
There is no association between resting SaO2 and ACE I/D genotype in Caucasian 
trekkers assessed at 4300m on Cerro Aconcagua. This study confirms the well 
recognized association between AMS and SaO2. 
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CHAPTER 6: Bradykinin 2 Receptor +9/-9 Polymorphism and High Altitude 
 
6.1 Background 
6.2 Methods 
6.2.1 Subjects  
6.2.2 Subject data 
6.2.3 Genetic Analysis 
6.2.4 Statistical Analysis 
6.3 Results 
6.4 Discussion 
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6.1 Background 
As a key component of the circulating RAS, ACE mediates its effects both through 
generation of vasoconstrictor Angiotensin II (AT II) and the degradation of vasodilator 
kinins.  The role of ACE in bradykinin degradation means that bradykinin levels are 
inversely related to ACE activity with the low circulating ACE levels conferred by the 
ACE I-allele associated with increased bradykinin levels (41, 42). Bradykinin is a 
potent endothelium-dependent vasodilator and increases vascular permeability (35). Its 
effects are mediated through the inducible bradykinin type 1 (BK1R) and constitutive 
type 2 (BK2R) receptors. The BK2R gene demonstrates a common functional 
polymorphism in which the absence (-9) of a 9 base pair repeat is associated with 
greater gene transcription (102), higher mRNA expression of the receptor (103) and 
lower vascular resistance (104). 
If the influence of the ACE I/D polymorphism on successful ascent to high altitude is, 
in part, mediated by altered levels of bradykinin, it may be postulated that the BK2R 
+9/-9 polymorphism might influence performance in a hypoxic environment. 
Supporting this hypothesis are data demonstrating that the +9/+9 genotype is associated 
with reduced metabolic efficiency during exercise in healthy subjects at sea level and 
the combined ACE I / BK2R -9 ‘high kinin receptor activity’ haplotype is significantly 
associated with endurance performance among elite athletes (105). 
I tested the hypothesis that inter-individual variations in AMS, peripheral SaO2 and 
successful ascent to high altitude may be influenced by the BK2R +9/-9 polymorphism. 
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6.2 Methods 
6.2.1 Subjects  
Subjects were the cohort of Caucasian mountaineers attempting to climb Cerro 
Aconcagua (6963m), and described in detail in Chapter 4. In brief, subjects were 
recruited soon after arrival at Plaza de Mulas base camp (4300m). Excluded were those 
who had spent more than 48 hours at 4300m, those taking steroids or acetazolamide for 
AMS prophylaxis and those taking RAS antagonists (ACE inhibitors, or angiotensin II 
type 1 receptor antagonists).  
 
6.2.2 Subject data 
 A buccal swab was obtained for genetic analysis, subjects completed a questionnaire 
and written informed consent was obtained from all volunteers (Questionnaire: 
Appendix 2). Success or failure in reaching the summit of Cerro Aconcagua (6963m) 
was self-reported by the subjects as they returned to record their safe return to Base 
Camp with the Aconcagua Park Rangers.  
Presence and severity of current AMS symptoms were documented using the Lake 
Louise Score (LLS) (Table 4.1). As used by others, a score of >4 was used to define the 
presence of AMS (118). 
SaO2 was measured using a pulse oximeter (MCDEI 8500M, Nonin Medical Inc, 
Plymouth, MN) placed on the index finger. SaO2 was measured with subjects resting in 
the sitting position. The saturation value was accepted when a stable result was 
displayed. Digits were pre-warmed to avoid poor pulse signals due to low perfusion. 
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6.2.3 Genetic Analysis 
For those who consented to take part, DNA was collected using a buccal swab and was 
genotyped for BK2R +9/-9 polymorphism (see Chapter 2: Methods for details). 
 
6.2.4 Statistical Analysis 
Results were analysed using SPSS version 21. Chi squared test was used to confirm 
Hardy-Weinberg equilibrium. Differences in study population physiological parameters 
and genotype groups for AMS incidence and severity were assessed by ANOVA or Chi 
squared testing as appropriate. Throughout, a p-value ≤0.05 was considered statistically 
significant.  
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6.3 Results 
During the study period, 110 (89 male) Caucasian subjects were recruited. BK2R +9/-9 
genotyping was successful in all subjects and the genotype distribution was 22 (20%) 
versus 59 (54%) versus 29 (26%) for +9/+9 versus +9/-9 versus -9/-9, respectively (+9-
allele frequency 0.468), consistent with the Hardy-Weinberg equilibrium. Bradykinin 
genotype was independent of age, sex, height and weight. At the time of assessment, the 
mean +/- SD duration of stay at 4300m had been 22.4+9.1 hours and there was no 
association between duration of stay and bradykinin genotype (p=0.182).  
 
AMS score and BK2R genotype 
There was a significant association between BK2R -9/-9 genotype and increased LLS 
with LLS by BK2R genotype of 2.00+1.54, 1.93+1.61 and 3.1+2.34 for +9/+9, +9/-9 
and -9/-9, respectively (p=0.016) (Table 6.1).  
Table 6.1 LLS by BK2R genotype 
 
 BK2R +9/-9 genotype Total 
+9/+9 +9/-9 -9/-9 
LLS 
0 5 15 4 24 
1 4 11 5 20 
2 4 11 3 18 
3 5 12 7 24 
4 3 6 1 10 
5 1 3 4 8 
6 0 1 3 4 
7 0 0 0 0 
8 0 0 2 2 
Total 22 59 29 110 
Mean LLS 2.00+1.5 1.93+1.6 3.1+2.3 2.03+1.7 
 p=0.016  
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AMS symptoms and signs and BK2R genotype 
Analysis of LLS breakdown demonstrated that this association in LLS was attributable 
to a strong association of BK2R -9/-9 genotype with the cardinal AMS symptom of 
headache (p=0.007) that was present in 15/29 (52%) of subjects with the -9/-9 genotype 
by comparison with 17/59 (29%) and 5/22 (23%) of those with +9/-9 and +9/+9 
genotype respectively (Table 6.2). The -9/-9 genotype was also significantly associated 
with difficulty sleeping (p=0.032). There was no association between BK2R genotype 
and the clinical assessment scores (Table 6.3). 
 
Table 6.2 AMS Symptoms by BK2R genotype  
  Headache Gastrointestinal Fatigue Dizziness Difficulty  Sleeping 
BK2R 
Genotype +9/+9 +9/-9 -9/-9 +9/+9 +9/-9 -9/-9 +9/+9 +9/-9 -9/-9 +9/+9 +9/-9 -9/-9 +9/+9 +9/-9 -9/-9 
Present 
(No of 
subjects)  
5 17 15 3 7 7 12 29 16 4 11 9 10 31 21 
Absent 
(No of 
subjects) 
17 42 14 19 52 22 10 30 13 18 48 19 12 28 8 
Symptom 
by genotype 23% 29% 52% 14% 12% 24% 55% 49% 55% 18% 19% 34% 45% 53% 72% 
% subjects 
 with  
symptom  
34% 15% 52% 23% 56% 
  p = 0.007 0.510 0.579 0.093 0.032 
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Table 6.3 AMS Clinical Assessment by BK2R genotype 
 
 
 
 
 
 
 
 
 
 
AMS presence and BK2R genotype 
However if a LLS ≥4 was used to define the presence of AMS, there was not an 
association between BK2R -9/-9 genotype and the presence of AMS (p=0.159) (Table 
6.4). Genotype distribution for the 24 subjects who suffered from AMS was 4 (16%) vs 
10 (42%) vs 10 (42%) (+9 allele frequency 0.375) and in the 86 subjects who did not 
suffer was 18 (21%) vs 49 (57%) vs 19 (22%) (+9 allele frequency 0.494) for +9/+9, 
+9/-9 and -9/-9 genotype respectively. 
 
Table 6.4 AMS presence and BK2R genotype 
 BK2R genotype Total 
+9/+9 +9/-9 -9/-9 
LLS 
0-3 18 49 19 86 
≥4 4 10 10 24 
Total 22 59 29 110 
AMS presence 18% 18% 34% 22% 
 p=0.159  
  Change in mental status Ataxia Peripheral oedema 
BK2R 
Genotype +9/+9 +9/-9 -9/-9 +9/+9 +9/-9 -9/-9 +9/+9 +9/-9 -9/-9 
Present  5 4 4 1 4 2 1 1 1 
Absent 17 55 25 21 55 27 21 58 28 
Sign 
by genotype 23% 7% 14% 5% 7% 7% 5% 2% 3% 
% subjects 
 with clinical 
sign 
12% 6% 3% 
  p = 0.428 0.750 0.870 
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SaO2 and BK2R genotype 
SaO2 was not associated with BK2R genotype with mean+SD SaO2 of 85.7+3.3, 
84.9+4.2 and 85.0+3.6 for BK2R +9/+9, +9/-9 and -9/-9 respectively (p=0.727). (Figure 
6.1) 
 
Figure 6.1 SaO2 and BK2R genotype  
 
 
Summit success and BK2R genotype 
Interestingly, given the association of BK2R -9/-9 with increasing AMS score, there was 
no consequent disadvantage associated with BK2R genotype and success in reaching the 
summit of Cerro Aconcagua (6963m) (Table 6.5). 
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Table 6.5 Summit success by BK2R genotype 
 BK2R genotype Total 
+9/+9 +9/-9 -9/-9 
Summit 
Success 13 37 18 68 
Failure 8 21 9 38 
Success rate 62% 64% 67% 64% 
 p=0.520  
 
BK2R genotype and ACE interaction 
When combined BK2R +9/-9 and ACE I/D haplotypes (e.g. ACE II and BK -9/-9) were 
assessed there was no association between any haplotype and AMS presence, Lake 
Louise Score, SaO2 or summit success.  
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6.4 Discussion 
 
This study is the first to demonstrate an association between the BK2R -9/-9 genotype 
and increased LLS. In particular the BK2R -9/-9 genotype is strongly associated with 
high altitude headache in subjects assessed after arrival at 4300m. There was no 
association demonstrated between BK2R genotype and SaO2 at 4300m or success in 
reaching the summit of Cerro Aconcagua (6963m). 
The finding that the BK2R -9/-9 is associated with increased severity of AMS and high 
altitude headache is novel and perhaps surprising given the existing literature that 
predominantly supports the -9 allele as associated with increased metabolic efficiency 
and improved athletic performance. The underlying pathophysiology of AMS and high 
altitude headache is not fully understood, but is thought to involve hypoxia-induced 
cerebral vasodilation and mild oedema, which, given the vasomodulatory and capillary 
permeability effects of bradykinin, suggests a bioplausible role for bradykinin in AMS 
susceptibility. (114, 116, 174-176). Recent evidence has advanced understanding of the 
development of AMS and reveals that hypoxia-induced cerebral vasodilation and 
potentially cerebral venous outflow restriction have a central role (115, 116, 177-179). 
The only previous study that has assessed the role of BK2R genotype in AMS 
susceptibility analysed 223 lowland Nepalese attendees to a religious festival at 4380 m 
in the Nepalese Himalaya and found no association with the BK2R -9/+9 polymorphism 
and susceptibility to AMS (180). However the authors noted that the +9/-9 allele 
frequencies in the Nepalese subjects were significantly different from those of other 
populations and the phenotypic consequences of BK2R genotype differ significantly 
between races (103, 104). They concluded that these variations limit the value of 
extrapolating their results to other populations and further association studies in other 
ethnic groups would be required to exclude the role of BK2R polymorphisms. 
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Exploring the potential contribution of bradykinin to the development of AMS, 
bradykinin is a potent endothelium-dependent vasodilator and has been demonstrated to 
have a role in the modulation of vascular resistance in humans, mediated in part by 
nitric oxide and endothelium-derived hyperpolarizing factor (37, 38, 181-183). 
Furthermore the BK2R +9/-9 polymorphism has been associated with differences in 
peripheral, systemic and pulmonary vascular tone (184-186). NO has been proposed as 
having a central role in high-altitude headache (187) and the effect of bradykinin as a 
powerful inducer of NO and further in the post translational regulation of eNOS (188) 
supports a bradykinin contribution to the development of AMS. High-altitude natives 
have shown a level of exhaled nitric oxide 25 to 200% greater than lowlanders (189), 
and greater levels of exhaled nitric oxide has also been demonstrated in mountaineers 
resistant to high-altitude illness (190). 
Whilst a plausible mechanism exists for a bradykinin influence on AMS and High 
Altitude Headache (HAH) development, the BK2R -9 allele has been associated with 
enhanced performance phenotypes and increased metabolic efficiency in previous 
studies, rather than the strong association of the -9/-9 genotype with AMS and HAH 
seen in this study (105, 106, 184, 191, 192). The mechanisms suggested for the 
influence of bradykinin and the BK2R +9/-9 polymorphism on physical performance 
include muscle blood flow and vascular resistance, skeletal muscle glucose uptake, 
nitric oxide (NO) mediated mitochondrial regulation and muscle fibre type (105). 
Bradykinin promotes glucose uptake in muscle (193, 194), the absence of the BK2R 
gene is associated with insulin resistance in mice (195) and the action of ACE inhibitors 
to increase whole-body insulin sensitivity is attenuated by BK2R blockade (196) and 
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may influence skeletal muscle glucose uptake and muscle blood flow (193). Through 
the BK2R, bradykinin enhances insulin-stimulated tyrosine kinase activity of the insulin 
receptor, with subsequent GLUT-4 translocation in skeletal muscle tissue during 
exercise (197). BK2R activation can lead to transient rises in inositol 1,4,5-trisphosphate 
(198), which is involved in excitation coupling of skeletal muscle (199) via increases in 
cytoplasmic calcium (200). This process is enhanced both by insulin and by inhibition 
of ACE (199, 201, 202).  
Bradykinin-induced nitric oxide (NO) generation may also modulate mitochondrial 
respiratory control (203). NO reversibly inhibits cytochrome-c oxidase in competition 
with oxygen and thus reduces VO2 in skeletal muscle and heart mitochondria (204). 
Tissue and whole animal studies have shown that kinins can suppress oxygen 
consumption via endogenous NO production in skeletal and cardiac muscle, an effect 
mimicked by ACE inhibition and prevented by blockade of BK2R (205, 206).  
It may also be that BK2R genotype influences skeletal muscle fiber type. The relative 
proportion of type I (slow twitch, oxidative) to type IIA (fast oxidative) and type IIB 
(fast glycolytic) skeletal muscle fibers has a strong influence on propensity to endurance 
or sprint performance (207) whereas ACE I/D genotype has been associated with fiber-
type distribution (83). 
However in this study no association was seen between BK2R -9/-9 genotype and 
physical performance, as assessed by summit success. It important to note that AMS 
susceptibility is not associated with sea level performance (116) and that it would not be 
physiologically inconsistent for a polymorphism that is associated with enhanced 
endurance performance to also be associated with increased susceptibility to the 
hypobaric hypoxia induced and unrelated condition of AMS.  Furthermore it is plausible 
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that the ‘high kinin’ phenotype associated with the -9 allele characterised by increased 
gene transcription (102), higher mRNA expression of the receptor (103) and lower 
vascular resistance (104) may accentuate the cerebral vasodilation and oedema 
responsible for AMS, and in particular the cardinal feature of high altitude headache, 
that is so strongly associated with the BK2R -9/-9 genotype in this study.  
Plausible mechanisms by which the BK2R polymorphism may influence SaO2 include 
altered capillary permeability and pulmonary vascular resistance (186) that may be 
hypothesised to predispose to pulmonary oedema and an increased diffusion barrier for 
oxygen. This study did not demonstrate any association between the BK2R +9/-9 
polymorphism and SaO2 at 4300m. Further evidence against such a hypothesis is 
provided by a study that found no association between the BK2R polymorphism and 
HAPE in 140 HAPE patients and 144 controls during the construction of Qinghai-Tibet 
railway (208). 
The ‘high kinin’ phenotype conferred by the ACE I and BK2R -9 haplotype has been 
associated with enhanced physical performance (105). This study did not demonstrate 
an association between any combined ACE I/D and BK2R +9/-9 haplotype. The lack of 
any association between either the ACE I/D or BK2R +9/-9 polymorphisms and high 
altitude performance, as assessed by successfully reaching the summit of Cerro 
Aconcagua (6963m), means that a haplotype association would be unlikely. Contrary to 
expectations of the -9 allele conferring an advantage at altitude, this allele has been 
demonstrated to be associated with increasing AMS score and high altitude headache 
which may counter any beneficial effect of increased metabolic efficiency. Finally it is 
unlikely that analysis of the 9 haplotype subgroups of the total group of 110 subjects 
would be sufficiently powered to demonstrate a significant difference.      
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As discussed in previous chapters this study has limitations, primarily imposed by the 
lack of control over the acclimatisation profile of subjects prior to their arrival at 
4300m. It is also noted that although an association exists between the BK2R -9/-9 
genotype and AMS score and previously between AMS score and SaO2, that no 
association is demonstrated between BK2R genotype and SaO2. This may be due to 
insufficient subjects to demonstrate a significant difference, although against this 
explanation there is no trend evident between genotypes, with mean+SD SaO2 of 
85.7+3.3, 84.9+4.2 and 85.0+3.6 for BK2R +9/+9, +9/-9 and -9/-9 respectively 
(p=0.727). Alternatively it may be that both BK2R -9/-9 genotype and low oxygen 
saturations are associated with increased AMS scores but in unrelated ways. 
 
Conclusion 
 
This is the first study to demonstrate an association between the BK2R -9/-9 genotype 
and AMS LLS and the presence of high altitude headache at 4300m on Cerro 
Aconcagua. This finding is consistent with current understanding of the development of 
AMS. No association with summit success or SaO2 was demonstrated.  
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CHAPTER 7: ACE I/D and BK2R +9/-9 genotype in Everest Summiteers 
 
7.1 Background 
7.2 Methods 
7.2.1 Ethics 
7.2.2  Subjects  
7.2.3 Subject Data 
7.2.4 Genetic Analysis 
7.2.5 Controls 
7.2.6 Statistical Analysis 
7.3 Results 
7.4 Discussion 
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7.1 Background 
Reaching the summit of Mount Everest (8848m) represents the world’s greatest 
environmental hypoxic challenge and nears the limit of human survival (2). A genetic 
influence on successful ascent to such extreme high altitude is supported by previous 
studies of elite mountaineers (86, 156) and by inter-individual differences in both 
acclimatisation to hypobaric hypoxia and susceptibility to AHAI (7, 8).  
Many environmental and logistical factors independent of individual performance 
influence success and survival in climbing the highest mountains in the world (5, 6). 
However, common to every successful mountaineer who has reached the summit of 
Mount Everest is a maintained ability to perform extreme physical exertion following a 
prolonged period of increasingly severe hypoxia (2). Acclimatisation to this degree of 
hypobaric hypoxia conventionally takes many weeks of residence at extreme high 
altitudes of >5500m with several successful forays to >7000m without supplemental 
oxygen prior to an attempt to climb to the summit. During the final ascent to the summit 
of Mount Everest (8848m), supplemental oxygen is used by over 96% of successful 
mountaineers and is commenced at altitudes between 7100m and 8300m at flow rates of 
0.5-4 litres per minute (2, 209). 
In 2006, a total of 1768 non-Sherpa climbers had reached the summit of Mount Everest 
(8848m) (5). If a genetic influence over performance at extreme high altitude exists, 
then polymorphisms that are associated with enhanced tolerance of hypobaric hypoxia 
ought to be over-represented in this unique group of elite hypoxic mountaineers. This 
study recruited mountaineers who had successfully climbed Mount Everest and tested 
the hypothesis that the allele frequency of ACE I/D and BK2R +9/-9, two candidate 
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polymorphisms believed to be associated with high altitude tolerance, should be over-
represented in this group when compared with race-matched non-mountaineer controls.  
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7.2 Methods 
7.2.1 Ethics 
The study was approved by the Joint UCL/UCLH Ethics Committee. Written informed 
consent was obtained from all volunteers. 
 
7.2.2  Subjects  
I attempted to recruit as many successful Everest summiteers as possible using two 
principal approaches: firstly email contact followed by postal pack and, secondly, 
recruitment of mountaineers attempting to climb Mount Everest at the North and South 
Base Camps.  
Email contact with Everest summiteers was achieved by several methods.  
1. A list of all Everest summiteers and limited contact details were available from 
online databases and mountaineering websites such as the Himalayan Database 
(www.himalayandatabase.com), Everest News (www.everestnews.com) and 
Explorersweb (www.explorersweb.com).  
2. Many of these summiteers identified were contactable by personal websites, 
professional mountaineering websites or through their public speaking agencies. 
3. To generate wider interest in the Everest community I placed advertisements and 
articles in the international mountaineering press and websites. 
4. I requested assistance from over 30 international mountaineering associations 
and clubs. Several organisations emailed their membership or forwarded contact 
details for all Everest summiteer members. 
5. I contacted all the commercial Everest expedition companies operating in 2006 
and requested assistance in contacting their previous successful Everest 
summiteers. 
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6. Through the successful recruitment of subjects and ongoing personal 
involvement in high altitude mountaineering I established a growing network of 
Everest community contacts who helped recruit further subjects. 
When an Everest summiteer agreed to participate in the study, a postal pack was sent to 
the subject’s address containing a questionnaire, consent form, and background 
information regarding the study (Appendix 3). Enclosed in the pack was a buccal swab 
collection kit consisting of a Whatman foam tipped applicator, Whatman FTA 
microcard, desiccating sachet, sealable pouch and instructions for use (Whatman 
Bioscience, Abington, Cambridge, UK). An international mail delivery envelope was 
enclosed to allow the subjects to return the completed consent form, questionnaire and 
sample without cost. 
Secondly, I personally recruited subjects at Everest North Base Camp in 2005 and 
arranged further recruitment by medical mountaineers who were visiting Everest North 
and South Base Camp in 2006 and 2007. An overview of subject recruitment is 
presented in Figure 7.1. 
Included in this study were mountaineers who have successfully reached the summit of 
Mount Everest and who, in response to a free text question requesting ‘Race’, self-
defined themselves as ‘white’, ‘white European’ or ‘white Caucasian’.   
 
7.2.3 Subject Data 
Subjects were asked, either in person or by post, to complete a questionnaire of 
demographic data, high altitude history mountaineering experience (Appendix 3) and 
details of date, route and oxygen use for the successful ascent of Everest. Self-reported 
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data were cross-referenced with the Himalayan Database for consistency and peer 
confirmation (www.himalayandatabase.com). 
 
7.2.4 Genetic Analysis 
DNA was collected using a buccal swab and was genotyped for ACE I/D and BK2R 
+9/-9 polymorphisms (see Chapter 2: Methods for details). 
 
7.2.5 Controls 
Published race-matched control allele frequencies were sought for the ACE I/D and 
BK2R +9/-9 polymorphisms.  
BK2R +9/-9 controls: The largest and closest race matched published control population 
who have been genotyped for BK2R +9/-9 identified was the cohort of 2541 unrelated 
healthy Caucasian subjects recruited from nine UK general practices (184). 
ACE I/D controls: Although larger ACE I/D genotyped control cohorts have been 
previously published, these studies have not been restricted to Caucasian subjects (210). 
ACE I/D allele frequency differs significantly between racial groups (152) and 
consequently the control population used in this study was a cohort of 462 white 
Caucasians who were selected by stratified random sampling of general practice lists in 
London (155). 
7.2.6 Statistical Analysis 
Results were analysed using SPSS version 21. Chi squared test was used to confirm 
Hardy-Weinberg equilibrium. Differences in study population physiological parameters 
and genotype groups were assessed by ANOVA, Chi squared or Fisher’s Exact testing 
as appropriate. Throughout, a p-value ≤0.05 was considered statistically significant.  
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7.3 Results 
 
Figure 7.1 Flow diagram of Everest Summiteer recruitment 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
402 Everest climbers 
recruited at Everest Base 
Camps: 
 
North Side 2005: 141 
North Side 2006: 43 
South Side 2006: 106 
North Side 2007: 112 
 
≈200 Everest Summiteers 
contacted by email 
 
268 successful Everest 
ascents  
125 postal packs sent  
 
333 Everest Summiteers 
(DNA samples and data) 	  
 
219 Caucasian Everest Summiteers 	  
65 completed packs received 
 
3 refusals 
≥75 no reply  
134 failed ascents 
 
60 not returned 
114 Non-Caucasian 
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Everest Summiteers 
Two hundred and nineteen Caucasian mountaineers who had reached the summit of 
Mount Everest (8848m) were successfully recruited to this study (Figure 7.1), of whom 
197 (90%) were male.  Only 6 subjects (2.7%) had reached the summit of Everest 
without oxygen. The mean+SD age at the time of reaching the summit was 39.4+9.1 
years, with height 178.7+7.8cm and weight 76.8+10.0kg. 
 
High altitude mountaineering history 
There was a wide variation in the reported high altitude mountaineering history. Everest 
Summiteers included in this study had climbed between 1 and 40 peaks of 7000-7999m 
altitude (mean+SD 3.8+5.6 ascents) and between 1 and 20 of >8000m (mean+SD 
2.2+2.4 ascents) (Figure 7.1 and 7.2). 
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Figure 7.2 Number of mountains 7000-7999m climbed by Everest Summiteers 
 
 
 
Figure 7.3 Number of mountains >8000m climbed by Everest Summiteers 
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ACE I/D genotype in Everest Summiteers 
ACE genotyping was successful in all of the 219 subjects and genotype distribution (58 
[26.5%] II, 102 [46.6%] ID, 59 [26.9%]; I-allele frequency 0.498) consistent with 
Hardy-Weinberg equilibrium. Height, weight and age were independent of ACE 
genotype.  
 
The I-allele was more prevalent in Everest Summiteers than in controls (0.498 vs 0.43, 
p=0.0196) (Table 7.1), the ACE II genotype being over-represented in this group 
(p=0.01). 
 
Table 7.1 ACE I/D genotype distribution in Everest Summiteers and controls 
 
 Everest Summiteers Controls 
II 58 (26.5%) 85 (18.9%) 
ID 102 (46.6%) 217 (48.2%) 
DD 59 (26.9%) 148 (32.9%) 
 p=0.01 
I-allele frequency 0.498 0.43 
D-allele frequency 0.502 0.57 
 p=0.019 
 
Values are numbers of individuals unless stated (percentage in brackets). 
 
 
 
 
  113 
Figure 7.4 ACE I/D genotype distribution (%) in Everest Summiteers and controls 
 
 
 
BK2R +9/-9 genotype in Everest Summiteers 
 
BK2R +9/-9 genotyping failed in 14 of the 219 subjects. In the remaining 205 subjects, 
genotype distribution (60 [29.3%], 102 [51.7%] and 39 [19.0%] for +9/+9, +9/-9 and -
9/-9 respectively; +9 allele frequency 0.55) was consistent with the Hardy-Weinberg 
equilibrium. Height, weight and age were independent of BK2R genotype.  
 
BK2R +9/-9 genotype distribution was not significantly different in the Everest 
Summiteer cohort compared to race matched controls (p=0.182) and similarly the +9 
allele frequency was not significantly different between the two groups (p=0.108) (0.55 
vs 0.51 in Everest Summiteers vs controls) (Table 7.2).  
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Table 7.2 BK2R +9/-9 genotype distribution in Everest Summiteers and controls 
 Everest Summiteers Controls 
+9/+9 60 (29.3%) 572 (26.0%) 
+9/-9 106 (51.7%) 1088 (49.6%) 
-9/-9 39 (19.0%) 535 (24.4%) 
 p=0.182 
+9 allele frequency 0.55 0.51 
-9 allele frequency 0.45 0.49 
 p=0.108 
 
Values are numbers of individuals unless stated (percentage in brackets). 
 
Mount Everest without supplemental oxygen 
Only 6 subjects reached the summit of Mount Everest without supplemental oxygen and 
the ACE and BK2R genotype of this group are displayed in Table 7.3. In this very small 
group there was no significant difference between the distribution of either genotype 
and that seen in the control group. 
 
Table 7.3 ACE I/D and BK2R genotype in Everest Summiteers who did not use oxygen. 
ACE genotype BK2R genotype 
II 3 +9/+9 1 
ID 1 +9/-9 4 
DD 2 -9/-9 1 
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7.4 Discussion 
This is the first study to assess genotype distribution in Everest Summiteers and 
demonstrates that the ACE I-allele is over-represented in this group of successful high 
altitude mountaineers compared to race-matched controls. This finding in a large cohort 
of 219 Caucasians, provides powerful confirmatory support to the hypothesis that the 
ACE I-allele confers enhanced performance in the hypoxic environment. It accords with 
published data demonstrating that the I-allele was over-represented in 25 elite British 
high altitude mountaineers (86) and associations with successful ascent to extreme and 
moderate high altitude (90, 110, 156). Whilst this study demonstrates that the ACE I-
allele is likely to confer an advantage in climbing to extreme high altitude, the strength 
of the association is less than that observed in a small group of elite British 
mountaineers who had climbed to over 8000m, amongst whom I-allele frequency was 
0.65 (86). Moreover Montgomery et al. did not find any of the elite mountaineer group 
to be homozygous for the D-allele, whereas in this study 2 of the 6 mountaineers who 
climbed Mount Everest without oxygen were of ACE DD genotype, as were 4 of the 6 
mountaineers who had climbed 10 or more 8000m mountains. 
No significant difference in allele frequencies was observed for the BK2R +9/-9 
polymorphism between Everest Summiteers and race-matched controls. The BK2R -9 
allele has been associated with enhanced performance phenotypes and increased 
metabolic efficiency in previous studies at sea level (105, 106, 184, 191, 192) but the 
single published study assessing the influence of the BK2R +9/-9 polymorphism at 
altitude demonstrated no association with the development of AMS in Nepalese 
pilgrims at 4380m (180). The BK2R +9/-9 polymorphism may have no influence on 
performance in the hypoxic environment or it may be that the -9 allele associated 
enhanced metabolic efficiency observed at sea level is offset by deleterious associations 
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at high altitude. The strong association of the -9 allele with AMS score and high altitude 
headache observed in Chapter 6 may provide an explanation for the lack of association 
of the BK2R +9/-9 polymorphism with high altitude performance if the -9 allele 
simultaneously confers both the advantage of metabolic efficiency and the disadvantage 
of high altitude headache. It may be proposed that the short lived duration of AMS on 
arrival to high altitude would be of little relevance to the 6-8 week period required to 
climb Mount Everest but mountaineers are sequentially exposed to higher altitudes 
during this period, culminating in a summit attempt, and may suffer from AHAI at each 
successive increase in altitude (2, 5). 
Although this study examines a cohort that has achieved extreme physical success in a 
profoundly hypoxic environment, a confounding factor is the use of supplemental 
oxygen. Supplemental oxygen is conventionally used during the summit attempt on 
Mount Everest (2, 209, 211) and provides both subjective benefit and improves SaO2 in 
the resting state and during exercise (212). Only 6 subjects (2.7%) of this cohort had 
climbed Everest without oxygen.  The remaining 213 subjects used supplemental 
oxygen and while they have not been exposed to a sustained PaO2 of 2.55kPa, as 
collected from an arterial blood gas at 8400m on Mount Everest (2), they have all 
demonstrated tolerance of a prolonged and profound but lesser degree of hypoxia. 
Whether this group would differ in genotype from a larger cohort of mountaineers who 
have reached the summit of Everest without oxygen is unclear but, if tolerance of 
hypoxia indeed has a genetic influence (7, 8, 184), the degree of hypoxic challenge that 
this cohort have successfully endured during the ascent of Everest would be expected to 
yield a group that is highly selected for this phenotype. 
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In a study of this kind, both cases and controls should be bio-geographically matched as 
closely as possible because the frequency of genetic variants, including the ACE I/D 
polymorphism (152), differ greatly across populations and can skew the results of a 
study. Bio-geographical matching of cases and controls was challenging in this study 
due to the international distribution and limited total numbers of Everest Summiteers. 
Subjects were asked to define their own race in this study and included in the analysis if 
they self-described as ‘white’, white – European’ or ‘Caucasian’, and subjects of Asian 
or African descent were excluded. The term Caucasian was self-defined and although it 
is widely used in the scientific literature, some view this as a term that carries racial 
overtones, and that technically refers only to people from the area between the Black 
and Caspian seas. The control groups selected were both large UK cohorts recruited 
from general practice lists and used the same racial descriptor of ‘white Caucasian’ 
(155, 184). Larger published control groups for the ACE I/D polymorphism exist but do 
not include descriptions of the racial composition of the cohort and so were not used 
(210).    
 
Conclusion 
This study demonstrates that the ACE I-allele is over-represented in mountaineers who 
have successfully climbed Mount Everest (8848m) when compared with race-matched 
controls and supports data suggesting that the I-allele is associated with enhanced 
performance in hypoxic conditions. 
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CHAPTER 8: Discussion 
 
The work in thesis explored the association between the ACE I-allele and human 
performance at high altitude. Prior to the studies in this thesis, an over-representation of 
the I-allele had been observed in a small group of 25 elite British mountaineers who 
climbed regularly to over 7000m (86).  No studies had attempted to replicate this 
finding in a larger group at extreme high altitude and the mechanism underlying such an 
association was unclear.  
I have demonstrated that the ACE I-allele is indeed associated with successful extreme 
high altitude performance in both a prospective study assessing success in climbing to 
8000m and with the observation that the I-allele is over-represented in mountaineers 
who have reached the summit of Mount Everest when compared to sea level, race-
matched controls. Moreover I have explored the mechanism underlying this association 
and demonstrated in 2 independent studies at various altitudes that the I-allele advantage 
is not mediated by susceptibility to AMS or by increased SaO2. These data regarding 
AMS accord with subsequent studies and meta-analysis (158, 159). 
The ACE I-allele advantage might be mediated via the role of ACE in bradykinin 
metabolism, the ACE I-allele conferring a phenotype of high kinin activity at the BK2 
receptor. If true, a similarly advantageous association should be observed with the 
BK2R -9 allele, and amplified by the combination of the ACE and BK2R -9 allele. In 
exploring this hypothesis, I demonstrated a novel and strong association between the 
BK2R -9/-9 genotype and the presence of high altitude headache and an increased AMS 
Lake Louise Score. This finding may be of importance in understanding the inter-
individual variation in the development of AMS and high altitude headache. A role for 
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bradykinin activity as a potent vasodilator and increasing capillary permeability in the 
development of AMS seems plausible, particularly in the context of a growing 
understanding that cerebral vasomodulation is central to the genesis of high altitude 
headache (116, 158, 159, 177-179). No association was demonstrated between the 
BK2R +9/-9 polymorphism and success in reaching the summit of Cerro Aconcagua 
(6963m) or any difference in allele frequency between Everest summiteers and race-
matched controls. 
Perhaps surprisingly given the strong association demonstrated between the I-allele and 
successful ascent to 8000m and a published study reporting an I-allele advantage at an 
altitude of 4807m (110), I did not demonstrate any association between the ACE I-allele 
and successful ascent to 5895m (Mount Kilimanjaro) or 6963m (Cerro Aconcagua). 
This lack of association in two independent studies at lower altitudes may be explained 
firstly by between-cohort differences between subject characteristics and, secondly, by 
differences between the physiological challenge posed by altitudes of 2700m to 6963m, 
and that experienced at altitudes of over 8000m. Both the Mount Kilimanjaro study and 
Cerro Aconcagua studies recruited subjects who were attempting to climb highly 
popular and non-technical mountains. It may be postulated that these subjects recruited 
on popular trekking peaks differ from mountaineers attempting to climb the highest 
mountains in the world, where I have demonstrated a clear association (156). This 
explanation is supported by a previous study where no association between ACE I/D 
polymorphism and performance was demonstrated when a large group of mixed ability 
and sporting disciplines were analysed together, but strong allele associations were 
revealed if outstanding athletes in specific disciplines were assessed (165). The authors 
concluded that associations with ACE I/D allele differ between disciplines and are most 
marked in elite performers. This interpretation may accord with lack of association 
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between the ACE I/D polymorphism and high altitude success in two cohorts of non-
elite high altitude trekkers. Secondly, the discordance seen between the two studies at 
8000m or higher that demonstrated association between the ACE I-allele and success, 
and the two studies at lower altitudes that did not, may be due to the extreme nature of 
the physiological challenge at 8000m that accentuates the influence of minor phenotypic 
advantages. There is clear precedence for phenotypic differences only being apparent at 
the extremes of human physiology in critical care research where interestingly the ACE 
I-allele has been associated with a lower mortality from acute respiratory distress 
syndrome (213), improved outcomes in childhood meningococcal septicaemia (214) 
and improved cardiorespiratory response to premature birth (215). 
This thesis describes a series of candidate-gene association studies where a genetic 
polymorphism is usually selected for investigation based upon the known or predicted 
function of the gene product that is believed to influence the phenotype of interest. 
More recently a candidate gene may be selected if it lies in an area of interest identified 
by genome-wide association studies (GWAS) that are used to simultaneously 
interrogate regional associations across all chromosomes (216). The sensitivity of 
candidate gene association studies depends on both sample and effect size, and 
identification of any association does not prove causation. Further cautions with 
candidate-gene association studies are that errors in multiple testing are possible, 
especially when a large number of polymorphisms are tested. To avoid such errors, my 
thesis has focused primarily on the ACE I/D polymorphism and secondarily 
investigated the B2KR +9/-9 polymorphism to explore whether the ACE I/D allele 
influence is mediated via kinin activity. 
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Although this thesis has investigated whether and how the ACE I/D polymorphism may 
directly influence high altitude performance, another explanation may be that the ACE 
I/D locus is either functionally related or in close linkage disequilibrium with a true 
causal locus that affects high altitude performance (217). It has been shown that 
polymorphic loci in the RAS act synergistically with one another in the pathogenesis of 
disease (208). Moreover, the ACE I/D polymorphism has been shown to act in such a 
manner with genes outside the RAS (218, 219).  
As discussed in previous Chapters, other potential limitations in the studies in this thesis 
include the variation of ACE I/D allele frequencies in different populations and, 
similarly to the wider literature studying the ACE I/D polymorphism and human 
performance that have generated conflicting results, ethnic and genetic differences in 
study groups (90). The advent of ancestry-informative markers (AIMs) (220) may 
reduce this as a confounding factor in future studies and will greatly facilitate 
quantification of sample stratification as well as reduce the reliance on self-reports or 
anecdotal data when defining the genetic backgrounds of study cohorts. 
The expedition environment introduces a number of confounding factors that are 
dissimilar to the controlled laboratory environment. Genetic associations may be 
obscured by factors such as cold, fatigue, dehydration, weather, logistics, accidents, 
concurrent illness, and environmental hazards and may influence the phenotypic traits 
of interest, such as summit success or AHAI  (6). It is even possible that genetic 
associations with summit success may be determined by tolerance or avoidance of one 
or more of these expedition environmental factors rather than hypoxia, although the 
association of ACE I/D with altered physiological responses to hypoxia in the 
laboratory environment make this less likely (112).    
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In recent years, novel developments in genetic and statistical techniques have been 
employed on both AHAI subjects and high altitude populations that may supersede the 
candidate gene analysis assessed in this study. Analysis of multiple candidate genes 
(221), whole genome amplification (222) and gene-gene interaction studies using 
multifactor dimensionality reduction (223) have revealed multiple additional 
polymorphisms, predominantly HIF related, that may be central to future understanding 
of the human response and adaption to hypobaric hypoxia. I attempted to reflect these 
advances in technology by undertaking whole genome amplification on the Everest 
Summiteer buccal swab samples. Unfortunately the buccal swab DNA collection and 
storage method used, the Whatman FTA microcard, did not yield sufficient DNA for 
analysis by this technique. Moreover there was insufficient DNA remaining to genotype 
for the B2KR +9/-9 polymorphism on the samples in Chapters 3 and 4 which explains 
the lack of uniformity of analysis across the experiments presented in this thesis. 
 
However, with the support of the novel findings that I have demonstrated in this thesis, I 
believe that there are several directions for future development of this work. More 
detailed physiological data such as that collected on the Caudwell Xtreme Everest 
expedition (224) would allow further elucidation of the role of the ACE I/D and B2KR 
+9/-9 polymorphisms than I achieved in these studies. In particular it would be 
fascinating to explore a B2KR +9/-9 association with the inter-individual variation in 
cerebral vasomodulation and AMS development identified previously (177, 178).  
In the final experiment of this thesis I have analysed DNA from 219 Everest 
Summiteers for ACE I/D and B2KR +9/-9 but have consent and ethical approval to 
analyse these samples for other polymorphisms associated with hypoxic performance. 
This is a unique and valuable cohort of elite hypoxic adaptors and, as novel hypoxia 
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associated polymorphisms in the HIF pathway (222) are identified by other techniques, 
it represents an ideal confirmatory dataset for additional hypoxia related candidate 
genes.  	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APPENDICES 
 
1. 8000m Questionnaire 
2. Aconcagua Base Camp (4300m) Questionnaire 
3. Everest Summiteer Questionnaire  
  125 
Appendix 1. 8000m  questionnaire 
 
1. Name (printed) and email: 
 
2. Race: 
 
4. Nationality: 
 
5. Age: 
 
6. Sex: 
 
7. Height: 
 
8. Normal weight: 
 
9. Mountaineering History 
 
How many times have you been: 
   
With Supplemental  Oxygen  Without Supplemental Oxygen 
 
6000-6999m 
 
7000-7999m 
 
8000-8848m 
 
10. What is the highest that you have ever climbed to? 
 
11. Have you suffered in the past from: 
 
HAPE (High Altitude Pulmonary Edema) 
 
HACE (High Altitude Cerebral Edema) 
 
For completion after summit attempt 
 
12. Maximum altitude reached: 
 
13. Did you use oxygen and, if so, from what altitude: 
 
14. If unsuccessful, reason for failure to reach summit: 
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Appendix 2. Aconcagua Base Camp (4300m) questionnaire 
 
1. Name (printed) and email: 
 
2. (Optional)  Contact details:  Address 
    
3. Race: 
 
4. Nationality: 
 
5. Age: 
 
6. Sex: 
 
7. Height: 
 
8. Normal weight: 
 
9. Do you have any disease or medical condition:  Yes No 
 
If Yes, what diagnosis / medical condition do you have: 
 
10. Are you taking any pharmaceutical drugs:  Yes No 
 
If Yes, what drugs are you taking: 
 
11. Mountaineering History 
 
How many times have you been: 
   
With Supplemental  Oxygen  Without Supplemental Oxygen 
 
3000-3999m 
4000-4999m 
5000-5999m 
6000-6999m 
7000-7999m 
8000-8848m 
 
12. Have you suffered in the past from: 
 
AMS (Acute Mountain Sickness) 
HAPE (High Altitude Pulmonary Edema) 
HACE (High Altitude Cerebral Edema) 
 
13. How many hours have you spent at this altitude (4300m): 
 
 
 
 
  127 
14. AMS Score at 4300m 
Symptoms:  1. Headache:  
No headache      0  
Mild headache     1  
Moderate headache     2  
Severe, incapacitating    3 
2. GI symptoms:   
No GI symptoms     0  
Poor appetite or nausea   1  
Moderate nausea or vomiting   2  
Severe nausea and vomiting, incapacitating  3 
3. Fatigue/weak:  
  Not tired or weak     0  
Mild fatigue/weakness    1  
Moderate fatigue/weakness    2  
Severe fatigue/weakness, incapacitating  3 
4. Dizzy/lightheadedness:  
Not dizzy      0  
Mild dizziness     1  
Moderate dizziness     2  
Severe, incapacitating    3 
5. Difficulty sleeping:   
Slept well as usual     0  
Did not sleep as well as usual   1  
Woke many times, poor night's sleep  2  
Could not sleep at all     3 
Total symptom score:     __ 
Clinical assessment: 6. Change in mental status:  
No change      0  
Lethargy/lassitude     1  
Disoriented/confused     2  
Stupor/semiconsciousness    3 
7. Ataxia (heel to toe walking):  
No ataxia      0  
Maneuvers to maintain balance   1  
Steps off line      2  
Falls down      3  
Can't stand      4 
8. Peripheral edema:  
No edema      0  
One location      1   
Two or more locations    2 
Clinical assessment score:     __ 
Total score:         __ 
 
15. Summit success (for completion after summit attempt) Yes No 
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Appendix 3. Everest Summiteer questionnaire 
 
1. Name (printed) and email: 
 
2. (Optional)  Contact details:  Address 
     Tel 
 
3. Race: 
 
4. Nationality: 
 
5. Age: 
 
6. Sex: 
 
7. Height: 
 
8. Normal weight: 
 
Mountaineering History 
How many mountains have you successfully summited? 
  With Supplemental  Oxygen  Without Supplemental Oxygen 
 
6000-6999m 
 
7000-7999m 
 
8000-8848m 
 
Everest 
On how many occasions did you attempt to climb Mt Everest, and by which routes? 
 
With Supplemental O2 (Y/N)  Successful?  (Y/N) Date Your age then 
1……… 
2……… 
3……… 
4……… 
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